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  Incidence 
 
Cutaneous melanomas (CM) are tumors with an unpredictable biological behavior. 
The incidence of cutaneous melanoma is still increasing worldwide, and despite 
significant advances in prevention, early detection and treatment, the mortality 
rate continues to increase steadily in certain countries.1-3 The current incidence 
rates vary dramatically throughout the world, ranging from as low as 0.2 per 
100,000 in China to as high as 40.5 per 100,000 among males in Australia.4 Mortality 
rates are more than fivefold lower than incidence rates and appear to be plateauing 
and declining in some groups. The highest mortality rate is reported from New 
Zealand and is estimated to be 5.3 per 100,000.4 Currently the incidence rate and 
mortality rate in the Netherlands are respectively 12.6 and 3.1 per 100,000 people, 
with 2100 new cases of melanoma being diagnosed in 1998.5 Because of early 
detection and treatment, melanomas are however being diagnosed at an earlier 
stage compared to in the past. This has led to an increase in the incidence of thin 
lesions (<1.00 mm Breslow thickness) among young individuals (those under the 
age of 65), with continuing increases in thick melanomas for males over the age of 
65.1 This is one of the reasons that the mortality rate has recently stabilized. 
However one in four patients will develop loco-regional recurrence and one in five 
patients will still develop distant metastases.6 
 
  Prognostic Factors and Staging 
 
The overall prognosis for patients who have localized melanoma without any 
nodal or distant metastases is good. The 5-year survival rates for patients with 
Stage I and II melanomas are respectively 93% and 68%.7 Several features of the 
primary tumor and lymphatic metastases have been examined as potential 
prognostic factors predictive for melanoma metastases. The analysis of the 
American Joint Committee on Cancer (AJCC) database on melanoma has 
confirmed that the risk of melanoma metastases increases with tumor thickness, 
the presence of ulceration, increasing age, anatomic site and nodal status.8  
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Breslow tumor thickness 
Breslow microstaging determines the thickness of the lesion, in millimeters, using 
an ocular micrometer to measure its vertical height. This was first described in 
1970 by Breslow in which he established a correlation between tumor thickness 
and survival.9 The risk of melanoma local recurrence increases with tumor 
thickness (Table 1).   
 
Thickness 
(mm) 
 
n Local 
recurrence 
(%) 
In transit 
metastases 
(%) 
Regional 
nodal 
recurrence 
(%) 
Distant 
metastases 
(%) 
1.00-2.0 445  (60%)  2.3  3.6  9.2  14.4 
2.01-3.0 215  (29%)  4.2  8.4  15.8  27.9 
3.01-4.0  77  (10%)  11.7 16.9 29.9 44.2 
Total 737  (100%)  3.8  6.4  13.3  21.4 
Table 1. Frequency of subgroups of thickness and incidence of local recurrence and other 
metastases.6 
 
Tumor ulceration 
Another factor associated with a greater risk for local recurrence is the presence of 
ulceration in the primary melanoma. When compared to non-ulcerated lesions, 
ulcerated melanomas are believed to represent a more biologically aggressive form 
of the disease that is associated with a worse prognosis. The presence /absence of 
ulceration was determined to be the second most powerful independent predictor 
of survival among factors analyzed by the American Joint Committee on Cancer 
(AJCC) behind Breslow thickness.8  
 
Tumor mitotic rate 
Recently researchers at the Sydney Melanoma Unit analyzed 3661 patients with 
regard to prognostic indicators and determined that tumor mitotic rate, and not _____________________________________________________________ 
ulceration, is the second most powerful prognostic indicator behind tumor 
thickness in regard to overall survival. If confirmed by studies from other centers, 
it has the potential to further improve the accuracy of melanoma staging.10  
 
MD Anderson Staging System 
The MD Anderson staging system is a four-stage system designed specifically to 
address the subset of patients with local, in transit, or satellite recurrences who 
were suitable candidates for isolated limb perfusion (Table 2). This staging system 
was used in chapters three and four, but is hardly longer used today. 
 
2002 AJCC TNM Melanoma Staging System 
In 2002 the new TNM AJCC staging system (Table 3 + 4) was completed and 
introduced as the new standard in melanoma staging.7 This staging was revised 
from the previous staging system in 1997. The major changes applied include 
incorporating the tumor thickness and ulceration directly into the T(umor) 
category and defining the N(ode) category by the number of metastatic nodes and 
not by the gross dimensions of the affected nodes (Table 3). This staging system 
was used in chapters five, six and seven.  
 
 
Stage Description 
IA  Primary tumor only 
IB Primary  excised 
IC Multiple  primaries 
II  Local recurrence (within 3cm) 
IIIA In-transit  recurrence 
IIIB  Regional nodal recurrence 
IIIC  In-transit and regional nodal recurrence 
IVA  Distant cutaneous metastases 
IVB  Distant visceral metastases 
 
 
 
 
 
 
 
 
 
 
 
Table 2. The MD Anderson staging system  
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T Classification  Tumor Thickness (mm)  Ulceration status 
T1  ≤1.0 
a. without ulceration and level II/III 
b. with ulceration or level IV/V 
T2 1.01-2.0 
a. without ulceration 
b. with ulceration 
T3 2.01-4.0 
a. without ulceration 
b. with ulceration 
T4 >  4.0 
a. without ulceration 
b. with ulceration 
N Classification  No. of metastatic nodes  Nodal metastatic mass 
N1 1  node 
a. micrometastasis 
b. macrometastases 
N2 2-3  nodes 
a. micrometastasis 
b. macrometastases 
c. satellite(s)/in transit metastases 
without metastatic nodes 
N3 
> 4 nodes, or in-transit 
metastases with metastatic 
nodes 
 
M Classification  Site  Serum LDH 
M1a 
Distant skin, subcutaneous or 
nodal metastases 
Normal 
M1b Lung  metastases Normal 
All other visceral metastases  Normal 
M1c 
Any distant metastasis  Elevated 
 
Table 3. The 2002 TNM AJCC melanoma staging system.7 _____________________________________________________________ 
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  Aims of the Thesis 
  
Over the past 35 years over two and a half thousand patients were treated for a 
primary cutaneous melanoma at the Groningen University Medical Center 
(GUMC). The GUMC is a referral center for over 2 million people located in the 
northern part of the Netherlands. Besides treating the usual cases of melanoma, an 
extensive experience in treating locally advanced melanoma has been developed 
such as hyperthermic isolated limb perfusion (ILP) and unusual cases of 
melanoma. Data from all of these patients has been collected and stored in a 
melanoma database. This database contains more than one-hundred patient, tumor 
and treatment characteristics. This thesis is based upon these patients and is 
divided in to two parts (A, B) 
 
  Part A   Hyperthermic Isolated Limb Perfusion 
 
Hyperthermic isolated limb perfusion was introduced in 1958 by Creech and 
Krementz.11 Six years later, in 1964 the first isolated limb perfusion for melanoma 
was performed by Oldhoff at the Groningen University Medical Center.12 The main 
advantage of this treatment modality is that a high dose of cytostatic drug can be 
delivered locoregionally without producing systemic toxicity. The indications for 
this treatment are inoperable local recurrence and in-transit metastases. Usage of 
this therapy in the adjuvant setting is discouraged since no benefit was seen in the 
multi-center EORTC trial.13  In chapter 2 a review of the history, indications, 
technique and refinement of the technique over the years is described. 
Traditionally the cytostatic drug used in the treatment of ILP in melanoma is 
melphalan (L-phenylalanine mustard, GlaxoSmithKline, London, England) and 
recently since the start of the nineties tumor necrosis factor α (TNFα; Boerhinger-
Ingelheim GmbH, Vienna, Austria) has been added to the regimen for bulky 
disease. A variety of other antineoplastic agents besides melphalan have been used 
during the last forty years in hyperthermic isolated limb perfusion such as 
darcarbazide (DTIC), actinomycin-D, thiotepa, mitomycine-C, doxorubicin and 
more recently cisplatin.14  ________________________________________                      C h a p t e r  I 
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Clinical Staging  Pathological Staging 
0  Tis N0  M0 0  Tis N0  M0 
IA  T1a N0  M0  IA  T1a N0  M0 
IB  T1b/T2a N0  M0  IB  T1b/T2a N0  M0 
IIA  T2b/T3a N0  M0  IIA  T2b/T3a N0  M0 
IIB  T3b/T4a N0  M0  IIB  T3b/T4a N0  M0 
IIC  T4b N0  M0  IIC  T4b N0  M0 
III  Any T  Any N  M0  IIIA  T1-4a N1a/N2a M0 
T1-4b N1a/N2a M0  IIIB 
T1-4a N1b/N2b/N2c M0 
T1-4b N1b/N2b/N2c M0 
 
IIIC 
Any T  N3  M0 
IV  Any T  Any N  Any 
M 
IV  Any T  Any N  Any 
M 
 
Table 4. 2002 TNM AJCC Stage groupings for cutaneous melanoma 
 
The majority of the cytostatic agents were or ineffective, or the duration of 
response quite limited, or when a drug showed effectiveness the local toxicity 
hampered the further application. _____________________________________________________________ 
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 In chapter 3 a derivative of cisplatin, carboplatin was used in a feasibility study 
with regard to effectiveness and toxicity.  Since the introduction of the pleiotrophic 
cytokine TNF α perfusionists have become more aware of the leakage of the TNFα 
to the systemic circulation. The most serious complication after TNFα perfusion is 
the systemic inflammatory response syndrome (SIRS) accompanied by fever, rise 
in cardiac output, fall in systemic vascular resistance and the need for fluid 
resuscitation and inotropes. If leakage exceeded the 2% limit during perfusion, 
there was less exposure of the tumor bearing limb to TNFα and an increased 
exposure of the patient systemic circulation to TNFα, resulting in more systemic 
side effects.15 It is therefore imperative to have an effective systemic leakage 
monitoring system. In chapter 4 our monitoring system which is based on 
continuous external monitoring with 131I-albumin as the main isotope was studied 
for its effectiveness in reducing the amount of patients with excessive leakage.  
 
  Part B   Uncommon aspects of melanoma 
 
In this part of the thesis certain uncommon aspects of melanoma are described.  
 
Pregnancy 
 Melanoma is often diagnosed in young adults and a significant number of these 
patients are women in their reproductive phase of life. The real incidence of 
melanoma during pregnancy is unknown. Smith and Randall reported in 1969 an 
incidence of 2.8 per 1,000 deliveries.16 The influence of pregnancy on the prognosis 
of melanoma has been a controversy ever since 1951 when Pack and Scharnagel 
reported ten pregnant patients with malignant melanomas of which five died 
within 30 months after diagnosis.17 Since then numerous case reports have also 
been presented showing a worse prognosis compared to non-pregnant women and 
the dilemmas in treatment policies.18,19  In  chapter 5 the long term effect of 
pregnancy and early stage melanoma was studied for the patients who were 
pregnant and treated for a melanoma at the GUMC.  
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Childhood and Juvenile melanoma 
Melanoma before puberty is rare, but the incidence increases steadily thereafter in 
each decade. The steepest trends of increasing incidence are in those aged over 65 
and the lowest trends are in the younger age groups. Approximately 1 to 4% of all 
new melanoma cases occur in patients under the age of 20 years and only 0.3% 
among those younger than 14 years.20-22 The highest rate is reported from Australia 
where 0.3% to 0.9% of the patients are under the age of 15.23  In chapter 6 we 
analyzed the childhood and juvenile melanomas treated at our institution with a 
special focus on differences in clinical characteristics, prognostic factors, disease 
free and overall survival in comparison with those of adults.  
 
Brain metastases from Head and Neck melanoma 
Cutaneous melanoma of the head and neck region comprise 10-20% of all 
melanoma.22,24,25 It has been reported that patients with head and neck melanoma 
have a worse prognosis than those with extremity or axial lesions, with an overall 
5-year survival of approximately 65%.26 However, if local recurrence develops the 
5-year survival drops to 36%.27  Melanoma represents the third most common 
cause for the development of brain metastases, after primary tumors of the lung 
and breast.28,29  The presence of brain metastases carries a worse prognosis in 
patients with metastatic melanoma and is one of the most common causes of death 
of this disease.30 The question has been risen as to if there is a difference in 
incidence in brain metastases between head and neck cutaneous melanoma and 
extremity/truncal melanoma and which risk factors are responsible for this 
difference. In chapter 7 we studied the patients with head and neck melanoma 
treated at the GUMC and which developed brain metastases in order to identify 
the risk factors associated with this devastating complication so that patients at 
highest risk can be monitored more closely and possibly treated earlier to improve 
the survival and quality of life. 
 
In summary, the aims of this thesis are:  
 
•  To investigate the experience of isolated limb perfusion in the treatment of 
cancer _____________________________________________________________ 
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•  To define the role of a new cytostatic agent carboplatin in the treatment of 
melanoma 
•  To evaluate the leakage of cytostatic agents during isolated limb perfusion 
•  To study the aspects of pregnancy in the treatment of melanoma 
•  To analyze the differences of childhood/juvenile melanoma in comparison 
to melanoma in adults 
•  To define the incidence and risk factors of brain metastasis in head and 
neck melanoma ________________________________________                      C h a p t e r  I 
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  Introduction 
 
Locally advanced melanoma or sarcoma of the limb was in the past surgically 
treated by an amputation of the affected limb. The majority of the patients died 
from their disease despite an amputation. This lead Klopp at the end of the forties 
to the idea to deliver a cytostatic agent, nitrogen mustard, direct to the tumor 
bearing limb through an intra-arterial injection, as a limb saving cancer treatment.1 
Shortly afterwards Sullivan developed the technique of continuous intra-arterial 
infusion.2 The idea behind the intra-arterial chemotherapy delivery was the ‘first 
pass through effect’ of the cytostatic agent. Morton and Eilber developed a 
combined modality for locally advanced limb sarcoma with three days regime of 
continuously intra-arterial doxorubicin with preoperative high dose fractionation 
radiation schedules of different dose levels in the late seventies.3 Today we know 
however that intra-arterial chemotherapy has no advantage over systemic, 
intravenous, drug delivery.4 
The theory behind the delivery of isolated regional chemotherapy is that a high 
drug uptake by the tumor may be achieved with higher doses of chemotherapeutic 
agents without increasing the systemic toxicity. The technique of isolated limb 
perfusion, a regional cancer treatment that allows the direct infusion of high doses 
of chemotherapeutic agents in the arterial supply of a tumor-bearing area of a limb, 
came available with the development of an extra-corporeal circuit for cardiac 
surgery. In the mid fifties the surgical-oncologists Creech and Krementz of the 
Tulane University in New Orleans developed the technique of the isolated limb 
perfusion.5 In the sixties Cavaliere reported on selective heat sensitivity of tumor 
cells and added hyperthermia within the regional perfusion technique.6 The 
ultimate goal of hyperthermia within the perfusion setting was increasing the 
blood flow and permeability of the cell membrane, therefore the drug uptake 
within the tumor by a synergistic effect, leading to an ultimate tumoricidal effect.  
The three major advantages of the delivery of chemotherapy within the isolated 
limb perfusion setting are: 1) the so called ‘first-pass’ effect resulting in an 
increased drug uptake, 2) hyperthermia facilitating drug uptake by increased 
blood flow and permeability of the cell membrane and 3) the use of cytostatic 
agents which cannot be used outside the isolated limb perfusion setting due to the 
high systemic toxicity. Key point in isolated limb perfusion is that the dose of ________________________________________                    C h a p t e r  I I 
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chemotherapeutic agents used, can be 15-20 fold the maximum systemic tolerated 
dose, since vital organs are isolated from the perfusion circuit.7 Since the first 
isolated limb perfusion was performed in the late fifties, the complex surgical 
technique is only used in a few cancer centers in the United States, Europe and 
Australia for the limb salvage treatment of locally advanced melanoma or soft 
tissue sarcoma. 
This chapter will review the technical aspects of the isolated limb perfusion 
procedure, the currently available cytostatic agents, the assessment of tumor 
response, the clinical results of adjuvant and therapeutic isolated limb perfusions 
for various malignancies of the limb, as well as the local and regional treatment 
toxicity and future directions. 
 
  Regional perfusion 
Perfusion level  
There are several levels for isolated limb perfusion in the upper and lower limb. 
Upper limb perfusions might be performed at the axillary level through the 
axillary artery and vein, or more distal upper limb perfusions through the brachial 
artery and vein. At the lower limb, perfusions might be performed at three 
perfusions levels, iliacal level through the external iliac artery and vein, femoral 
level through the femoral artery and vein, and at the distal thigh above the knee 
through the popliteal artery and vein. (Fig.1) The level of perfusion is determined 
by the involved part of the limb and the kind of disease, e.g. skin malignancies 
versus sarcomas. For skin malignancies the most proximal site of cannulation is the 
best choice, since the whole limb is at risk. In sarcoma the perfusion level is defined 
b y  a  d i s t i n c t i o n  p a r t  o f  t h e  l i m b s  c o n t a i n i n g  t h e  t u m o r .  I n  c a s e  o f  l i m b  
recurrence(s) repeated perfusions might be possible, preferably at another level, to 
reduce the risk of complications to the previous exposed and perfused vessels.  
Perfusion technique 
During the perfusion the limb is exclusively perfused. After dissection of the 
appropriate artery and vein and ligation of the collateral vessels, to control _____________________________________________________________ 
collateral flow and prevent leakage, the patient is heparinized systemically 
(heparin 3.3 mg/kg body weight). 
 
 
 
Fig.1  Five different perfusion levels for regional perfusion of the extremities. 
 
The limb is isolated from the systemic circulation by an esmarch bandage twisted 
around the root of the limb and fixed around a pin inserted into the head of the 
humerus (axillary perfusion) or iliac crest (iliacal perfusion). An inflating 
tourniquet (300-400 mm Hg) is used for brachial or popliteal perfusions. The artery 
and vein are exposed, cannulated with 14 to 16 F catheters, connected to an 
extracorporeal circulation system and perfusion flow is initiated in the circuit. 
Thermister probes are placed in the subcutaneous tissue and muscle for continuous 
temperature monitoring. The perfused limb is wrapped in a thermal blanket to 
reduce heat loss. (Fig.2) The extracorporeal circulation perfusion system consists 
out of a roller pump, a membrane oxygenator, and a heat exchanger. The 
extracorporeal perfusion equipment improved during the last four decades with all 
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kinds of continuous data monitoring systems; recording of the temperature of the 
perfusate, the mean arterial and venous pressure in the perfusion canules, mean 
arterial pressure in the system, venous saturation and electronic balance of the 
perfusion volume. The perfusion group of the Groningen University Hospital 
further improved the perfusion technique by introducing the pressure-regulated 
perfusion, as well as safety by improvement in continuous leakage monitoring.8,9  
The perfusate priming used in Groningen is oxygenated by a membrane 
oxygenator DIDECO 902 (DIDECO, Mirandola, Italy) with a gas mixture of air and 
O2 , consisted of 250 ml Isodex in saline 0.9% (NPBI International BV, Emmer 
Compascuum, The Netherlands), 250 ml white cell-reduced (filtered) packed red 
cells, 30 ml of 8.4% NaHCo3 , 0.5 ml 5000 IU/ml heparin. Leakage into the systemic 
circulation is continuously monitored with radioactive tracers. A small calibration 
dose of radioactive Iodine-131 labeled human serum albumin, (RISA 0.5 MBq) and 
a dose of radioactive Technetium-99m labeled human serum albumin (RTcSA 10 
MBq) are administered into the systemic circulation after surgical isolation of the 
limb is accomplished. The day before surgery the thyroid is saturated by the oral 
administration of iodine. A ten times higher dose of RISA (5MBq) is injected to the 
perfusion circuit. The 364-keV gamma rays emerging from the RISA and the 140-
keV gamma rays from the RtcSA are measured with a NaI detector over the 
precordium. Leakage from the perfused limb to the systemic circulation results in 
an increase of the baseline level, continuously measuring the percentage of leakage 
from the perfusion solution into the systemic circulation. The risk of leakage is 
mainly related to the level of perfusion, and is in general less than 3%.9  
The perfusions are flow regulated on the basis of arterial and venous pressure. To 
achieve adequate tissue perfusion during clinical regional perfusions, the 
extracorporeal circuit must be regulated at a delta pressure of 15 mm Hg between 
the pressure in the arterial and venous catheter.8 Cytostatic agents are added 
directly into the arterial line of the perfusion circuit as soon as a limb temperature 
of 380 C is reached. Perfusions are performed during 60 minutes under mild 
hyperthermia (390-400 C). Adjustments of the flow rate and the pressure in the 
perfusion circuit by the perfusionist, as well as the blood pressure in the patient by 
the anesthesiologist, together with an optimal isolation of the limb by the surgeon, 
ensure a stable and therefore optimal perfusion. _____________________________________________________________ 
 
Fig.2 Schematic drawing of a regional perfusion circuit for an iliacal perfusion of the lower 
extremity; esmarch bandage around the hip with Steinman pin inserted in the iliac crest, 
arterial and venous perfusion catheters connected to the arterial and venous line, membrane 
oxygenator, heat exchanger, roller pomp, leakage monitoring with scintillation detector 
placed over the heart, warm water mattress and thermo probes for skin and muscle 
temperature. 
 
When there is an increase leakage to the systemic circulation (losing), the flow rate 
should be reduced and the systemic blood pressure increased, eventually the 
tourniquet tightened, while with a loss of the systemic circulation into the 
perfusion circuit (gaining) the tourniquet should be tightened, flow rate increased 
and outflow ‘occluded’.9 I n  c a s e  o f  t o o  m u c h  l e a k a g e ,  l o s i n g  o r  g a i n i n g ,  t h e  
perfusion should be terminated for technical reasons to prevent eventual loco-
regional or systemic complications. After the perfusion the limb is extensively 
washed out with 4-6 L of saline and the limb filled with 250 ml white cell-reduced 
(filtered) packed red cells. The vessels are restored, first the vein and secondly the 
artery to ensure adequate outflow of the limb. Finally the heparin is antagonized 
with prothrombin and a fasciotomy is performed. Patients perfused with tumor 
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necrosis factor α (TNFα) are monitored during 24 hrs on the intensive care, while 
patients perfused with melphalan are observed on the ward. No prophylactic 
antibiotics are prescribed. Patients receive subcutaneous low-dose molecular 
heparine till a full mobilization is achieved.  
Cytostatic agents 
Cytostatic agents used in isolated limb perfusion must have appropriate 
pharmacokinetic profiles such as steep dose-response curves without requiring 
metabolic activation. The most optimal cytostatic agents must therefore have a 
high degree of extraction within the perfused limb and a high total body clearance 
in case of systemic leakage. The real advantage of cytostatic agents used in the 
perfusion setting should be expressed by comparing the area under the curve of 
the concentration versus time profile using the perfusion drug application versus 
the conventional intravenous drug delivery.10 
The first drug used in isolated limb perfusion by Creech and Krementz was 
melphalan.5 A variety of other antineoplastic agents besides melphalan have been 
used during the last forty years in hyperthermic isolated limb perfusion such as 
darcarbazide (DTIC), actinomycin-D, thiotepa, mitomycine-C, doxorubicin and 
more recently cisplatin and carboplatin. The majority of the cytostatic agents were 
or ineffective, or the duration of response quite limited, or when a drug showed 
effectiveness the local toxicity hampered the further application. Doxorubicine 
showed effectiveness but disturbed the arterial vascularity of the limb, while 
cisplatin and carboplatin were too neurotoxic.11-14 
Mephalan (L-phenylalanine mustard, GlaxoSmithKline, London, England) is an 
alkylating agent of the bischloroethylamine type compromising of nitrogen 
mustard and phenlylalanine. Phenylalanine is a metabolite of melanin and 
therefore melphalan specially targets melanocytes and melanoma cells. Its 
cytotoxicicity appears to be related to the extent of its interstrand cross-linking 
with DNA. Like other bifunctional alkylating agents, it is effective against both 
resting and rapidly dividing tumor cells. Melphalan is widely used since the sixties 
and the standard, most effective drug in the isolated limb perfusion setting for 
melanoma.  _____________________________________________________________ 
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The dose calculation of chemotherapeutic agents in the past performed was on 
body weight. The dosage melphalan was 1.0–1.5 mg / kg for the lower limb and 
0.5–0.7 mg / kg for the upper limb.  The maximally tolerated dose of melphalan by 
this method of calculation without regional toxicity is thought to be 1.75 mg / kg, 
while 2.0 mg / kg will lead to severe regional toxicity.15 Today the dosage is based 
on the perfused limb volume which seemed to be more appropriate.16 The volume 
of the perfused limb is determined before surgery by immersion. The current 
melphalan dosage used is 10 mg / L limb volume for the lower limb and 13 mg / L 
limb volume for the upper limb. The maximal tolerable dose is 16 mg / L limb 
volume. Doses greater than 150 mg per limb results in dose-limiting regional 
toxicity.17  
The systemic use of Tumor Necrosis Factor-alpha (TNFα; Boerhinger-Ingelheim 
GmbH, Vienna, Austria) is a pleiotrophic cytokine was abandoned due to its 
vasoplegia effect resulting in a severe septic shock syndrome. To use the potential 
effect of TNFα, e.g. tumor vessel destruction while limiting the side effect, e.g. 
septic syndrome. In the late nineties Lejeune introduced TNFα in the perfusion 
setting together with melphalan in the treatment of locally advanced melanoma 
and sarcoma of the limb.18 The exact working mechanism of TNFα is still unknown, 
but progress is being made. TNFα attacks the neo-vascular endothelial cells in 
particular the tumor vasculature with rapid elimination of tumor blood flow 
during the treatment. Binding of TNFα to its endothelial receptors induces a 
cascade of mechanisms which suppress anticoagulant mechanisms and support 
thrombus formation in the tumor vessels, causing circulatory stasis and ischemia 
inside the tumor, followed by necrosis of the tumor. E-selectin, VCAM, ICAM-1, 
tissue factor and deactivation of an integrin (αvβ3) are all contributors in this 
cascade. Morphological changes of the endothelial cells with overlapping and 
elongation of the cell results in increased vessel permeability, facilitating the drug 
uptake of melphalan within the tumor cells.19 
Is it possible to hence tumor response to TNFα? Endothelial monocyte-activating 
polypeptide II (EMAP-II) is a novel tumor-derived cytokine that sensitizes tumor 
vasculature to the effects of systemic TNFα. Tumor necrosis factor receptor I (p55) 
is upregulated on endothelial cells by exposure to the tumor-derived cytokine 
EMAP-II. Furthermore EMAP-II induces apoptosis and has antiangiogenetic 
effects. In an experimental rat-model Eggermont and co-workers showed indeed ________________________________________                    C h a p t e r  I I 
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the improved antitumor response to isolated limb perfusion with TNFα after 
upregulation of EMAP-II in STS.20  
Since the introduction of TNFα in the perfusion setting various clinical and 
experimental studies have been performed to get more insight in the working 
mechanism of TNFα. Pre- and postperfusion angiography clearly showed that 
TNFα produces a selective destruction of the tumor-associated vessels, while the 
normal vasculature remained intact.21 The dosage of TNFα is 3 mg for the upper 
limb and popliteal perfusion, while 4 mg is used for the lower limb. None 
randomized studies showed however that 1 mg TNFα might be even effective as 
the usual used 3 or 4 mg dosage.22 Melphalan concentrations in the perfused limb 
decrease from time zero to 10-20% of the initial dosage by 60 minutes. In the initial 
first 5-10 minutes there is a rapid decrease of melphalan due to the uptake by the 
tissue, while during the remaining perfusion time there is a continuously 
degradation of the drug as well as an adherence to the plastic tubes surface of the 
perfusion circuit. To receive an optimal effect of the melphalan a minimal 
perfusion time of 45 minutes is required. In contrast TNFα is almost immediately 
binded to the pathological endothelial cells, and a so-called ‘TNF priming time’ of 
15-30 minutes prior to the intra-arterial delivery of melphalan seems appropriate. 
Based on experimental studies the clinically used perfusion time for melphalan 
alone is 45-60 minutes and for the combined TNF-melphalan perfusion 60-90 
minutes.23 
Assessment of local tumor response 
Clinical assessment of tumor response is defined by the World Health 
Organization criteria.24  Complete response (CR) is defined as the disappearance of 
all measurable disease in the limb for longer than four weeks, partial response (PR) 
as regression of the tumor size by >50% for longer than four weeks, and no change 
(NC) as regression of <50% of the tumor or progression of <25% for longer than 
four weeks. Assessment is possible by physical examination and/or 
radiodiagnostic imaging. An MRI is used t o  m e a s u r e  t h e  r e s p o n s e  i n  s i z e  f o r  
sarcoma. Today there are techniques to measure non-invasive in-vivo responses 
available. The currently most widely and available technique is Positron Emission _____________________________________________________________ 
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Tomography (PET) which measures the tumor metabolism.25 New promising 
techniques such as bioluminescent imaging (BLI) are under development.26  
The perfusion technique is a local regional cancer treatment with the ultimate goal 
to improve the limb salvage rate in locally advanced limb melanoma and sarcoma. 
There are no randomized studies performed as ultimate proof of the concept but 
the advantage of the technique in the limb salvage rate and local control of the 
disease is demonstrated in the various studies. The question if assessment of tumor 
response after isolated limb perfusion is a predictor of disease outcome is still 
unanswered. PET studies performed after TNF perfusions for locally advanced 
sarcomas provided insights in the effect of treatment, varying from CRs to NCs. 
Pre- and postperfusion Positron Emission Tomography (PET) showed as a result 
the rapid disappearance of tumor hypermetabolic areas linked to the 
hypervascularization.27,28 Extensive pathological examinations of resected soft 
tissue sarcomas showed however in the majority of the specimens ‘vital’ tumor 
cells at the surrounding of the necrotic specimen.27,28 Clinical, as well as in-vivo 
assessment of tumor response is a valuable predictor for the final effect of the 
regional treatment, which is a matter of course not translated to the overall 
outcome of the disease.  
 
  Isolated limb perfusion  
Melanoma 
In the beginning isolated limb perfusion was used as a therapeutic treatment for 
locally advanced melanoma, recurrences and/or intransit metastases. Later on 
adjuvant limb perfusions were introduced in the treatment of melanoma of the 
limb. Over the last three decades many papers on hyperthermic isolated limb 
perfusion for melanoma combining adjuvant perfusions with therapeutic 
perfusions, often with different treatment schedules have been published and no 
conclusion could be drawn.29 Finally a randomized trial showed (EORTC 
18832/WHO-15/NAPG-1) no real benefit of hyperthermic isolated limb perfusion 
as an adjuvant treatment modality for patients with high-risk stage I melanoma (> 
1.5 mm Breslow thickness).30 On the otherhand isolated regional perfusion with 
melphalan is a well accepted treatment for intransit metastases and/or recurrences ________________________________________                    C h a p t e r  I I 
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in patients who are no longer candidates for local treatment, e.g. surgery, 
cryotherapy or laser treatment. Complete response rates of 40-60% with an overall 
response rate of 80% might be expected after therapeutic perfusions, while the 
addition of mild hyperthermia adds little to a normothermic perfusion.31 Although 
double perfusions might increase the reponse rate further, this will have however 
no effect on frequency, time to local recurrence as well as time to distant failures, 
or survival.32 Patients who did not achieve a complete response do worse than 
patients with a complete response. Roughly one third of the complete responders 
will recur, an additional one third will develop distant recurrences and the 
remaining one third will remain disease free. Perfusions performed in patients 
with recurrences after previous perfusions might render one third of these patients 
again disease free.  
Other chemotherapeutic agents have been used in melanoma perfusions, showing 
lower subjective response rates and often higher toxicity. The most effective 
systemic agent in the treatment of melanoma is DTIC, but used in the perfusion 
setting this agent leads to complete response rate of 11% and a partial response rate 
of only 26%.33 Cisplatin is one of the most successful alternatives with of 50-60% 
response rates, but showed a too high frequency of peripheral neuropathy.13   
After the initial successful experience in the early nineties of isolated limb 
perfusion for melanoma with TNFα, gamma interferon, and melphalan (TIM) with 
90% CRs, Lejeune and co-workers initiated a prospective randomized phase II 
study of patients with advanced melanoma of the limb by comparing TIM-
perfusion versus TM-perfusion. The study showed a 10% drop in CR when 
interferon was omitted, but the difference was not significant.34 A comparison with 
matched cases from a databank confirmed that melphalan only results in 52% 
complete responses.34 The study was early terminated due to the fact that TNFα 
and melphalan showed overall no real benefit, compared to melphalan alone with 
a median survival of 2.5 years. Patients with low tumor burden or small tumors 
showed equivalent results were documented (TNFα and melphalan versus 
melphalan), while TNFα and melphalan showed higher response rates in bulky 
melanoma. Therefore melphalan is the drug to be used in melanoma perfusion and 
combined with TNFα when bulky disease or recurrent disease after previous 
melphalan perfusion is the indication for perfusion. The key question if a TNF _____________________________________________________________ 
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perfusion has advantage over a perfusion with melphalan alone is still 
unanswered, and results from the American College of Surgeons melanoma 
perfusion trial (03-C-0137) are pending. 
Sarcoma 
Soft tissue sarcomas (STS) are relatively rare malignancies of different 
mesenchymal derivation, accounting for less than 1% of all cancer in adults. 
Roughly fifty percent of all sarcomas are located in the extremities, and fifty 
percent of them are over the age of 65 years.34 Although isolated limb perfusion 
was developed in the treatment of melanoma of the limb, the procedure was 
shortly after the introduction also applied in the treatment of soft tissue sarcoma of 
the limb. In the first experience Krementz s h o w e d  a n  e a r l y  r e s p o n s e  r a t e  a f t e r  
melphalan of 83%, however complete regression of the tumor was hardly seen.36 
The first breakthrough in the limb saving treatment of sarcomas was achieved in 
the eighties, when limb saving treatment, with or without adjuvant radiation 
treatment, showed the same disease free and overall survival as amputation.37 The 
isolated limb perfusion program at the Groningen University, as elsewhere, was 
stopped, when the results achieved with the complex perfusion technique were not 
better than after surgery and adjuvant high dose irradiation.38,39 
Although the combined modality treatment of surgery and adjuvant radiation 
improved the limb salvage rate of limb sarcomas, an amputation of the limb was 
still unavoidable in 5-10% of these patients. Other perfusions agents in the 
treatment of limb sarcomas were therefore investigated. Rossi claimed efficacy of 
doxorubicin in the perfusion setting for limb sarcomas, while another study 
proved that doxorubicin alone was ineffective and combined with melphalan too 
toxic. 40,41 Cisplatin showed also to be ineffective in the limb perfusion setting of 
sarcomas. 12,42 Although adjuvant chemotherapy may reduce the local failure rate in 
some patients, (neo) adjuvant and adjuvant chemotherapy had no beneficial effect 
in improving the limb salvage rate, disease free and/or overall survival in 
extremity sarcoma.43 
The second breakthrough in the treatment of locally advanced soft tissue sarcoma 
of the limb came with the introduction of TNFα and melphalan in the perfusion 
setting by Lienard and Lejeune in the early nineties.18  After TNFα perfusion, 
remarkable tumor shrinkage might be encountered within 6-12 weeks. Irresectable ________________________________________                    C h a p t e r  I I 
 
  37 
sarcomas become resectable. Complete response rate of 18% and partial response 
rates of 64% by measuring the tumor size was achieved.44 Various reports have 
shown that a limb salvage rate of roughly 80% can be achieved in patients with 
primarily irresectable limb sarcoma. Since the resection margins in these tumors 
are minimal, and often viable tumor cells are encountered at the periphery of the 
tumor adjuvant radiation is applied to ensure local tumor control. Adjuvant 
irradiation is well tolerated after previous intensive combined modality treatment 
of perfusion and extensive surgical resection.45 TNF perfusion is now applied over 
a decade and in surviving patients we encounter now the long term treatment 
related morbidity necessitating amputation.46 
A large European study proved the ILP concept in the limb salvage procedures for 
irresectable STS with TNFα and melphalan. The objective response rate was 76%. 
A limb salvage rate of 71% was achieved with a minimal treatment related 
morbidity.47An independent review committee considered that 80% of all enrolled 
patients in this study met indeed the criteria for irresectability and survival curves 
based on a match control study with cases of the Scandinavian Soft Tissue Sarcoma 
Databank showed that TNFα had no negative effect on survival.48 Further analysis 
showed that ILP-patients survived as long as matched controlled conventionally 
treated patients.49 The outcome of the ILP procedure in ‘elderly’ sarcoma patients 
was in general not different from the ‘younger’ sarcoma patients.50 Perfusions in 
elderly limb sarcoma patients can on the otherhand sometimes not be performed 
due to atherosclerotic changes in the main arteries and/or severe co-morbidity. For 
these patients an amputation of the limb is unavoidable. With the improved 
surgical perfusion techniques, the perioperative care and intensive care facilities, 
perfusion treatment related morbidity for limb sarcoma is minimal.  
Lymph edema-associated angiosarcoma, the Stewart-Treves syndrome, may be 
diagnosed in patients who underwent a mastectomy for breast cancer or axillary 
dissection for melanoma. The Stewart-Treves syndrome is extremely rare and the 
pathogenesis is not completely understood. The TNFα perfusion is an excellent 
indication for the limb salvage treatment for patients who where previously 
candidates for ablative surgical procedures.51 
The results of the multicenter TNF study performed in the nineties lead to the 
approval of using Beromun® (Boerhinger-Ingelheim GmbH, Vienna, Austria) and _____________________________________________________________ 
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melphalan. (GlaxoSmithKline, London, England) for isolated limb perfusion 
treatment of locally advanced extremity sarcomas. Beromun® is not registered in 
the United States. Currently isolated limb perfusion with TNFα is worldwide 
available in more than 30 Centers. In 2002, 350 so called TNF-perfusions were 
performed. Why do not all the perfused sarcomas respond after a TNFα? 
Multidrug resistance is a major issue in chemotherapy treatment. Two groups 
investigated separately the expression of multidrug resistance in patients 
undergoing TNFα perfusion treatment. Hohenberger et al. investigated the 
expression of multidrug resistance genes major vault protein (MVP), MDR1, and 
MDR-associated protein 1 (MRP1) before, during and after isolated limb perfusion 
for sarcoma or melanoma. In 83% of the patients, MVP expression was induced 
during perfusion, while inductions of MDR1 and MRP1 were observed in only 13% 
and 27%. The temperature and the drugs were therefore unable to induce MDR1 
and MPR1 in the majority of these tumors in the perfusion setting.51 Komdeur et al. 
investigated the expression of P-glycoprotein (P-gp), MDR1, and lung resistance-
related protein (LRP) in relation to the clinical outcome of TNFα perfusion 
treatment for extremity sarcomas. The sarcomas were more often positive for P-gp, 
than for MRP1. The MDR status was not predictive for tumor response after TNF-
I L P .  D a t a  o f  t h e  s t u d y  s h o w e d  a l s o  t h a t  T N F α perfusion did not induce MDR 
positive sarcomas.52 This is an important finding, since systemic doxorubicin based 
polychemotherapy is currently investigated in soft tissue sarcoma patients after 
TNFα perfusion as an adjunct within the EORTC trial 62931. The combination of 
TNFα and melphalan is currently the standard drug combination in isolated limb 
perfusion for the limb salvage treatment of primarily irresectable soft tissue 
sarcoma of the extremities, but there are still 20-30% of the tumors that will not 
respond. Therefore agents synergistic with TNFα must be investigated such as 
doxorubicin, or actinomycin-D. The combination of TNFα and doxorubicin was 
recently clinically investigated showing no benefit when compared to TNFα and 
melphalan.54 Seynhave et al. showed in an experimental perfusion study in the rat-
model that the combination of actinomycin-D and TNFα improved the tumor 
response in the soft tissue sarcoma bearing rats. The responses were unfortunately 
accompanied by severe, dose limiting, local toxicity; a synergistic anti-tumor 
response with idiosyncratic locoregional toxicity to the normal tissues.55 These ________________________________________                    C h a p t e r  I I 
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experiments don’t warrant the further clinical investigation of these two drugs in 
isolated limb perfusion for sarcomas. 
Miscellaneous tumors 
Isolated regional perfusions with TNFα have been successfully performed for in 
patients with locally advanced squamous cell carcinoma and Merkel carcinoma not 
amenable to local surgery with response rates of 87% (CR 60%, PR 27%).56 There is 
also a limited perfusion experience with cisplatin, as well as with TNFα for 
unresectable bony sarcomas.12,57 No conclusion can be drawn from these studies. 
 
  Treatment toxicity 
 
The treatment toxicity can be categorized as side effects from systemic exposure to 
the cytostatic agent and as side effects due to the regional effects of the high-dose 
exposure and hyperthermia. The vast majority of perfusions can be performed 
with systemic drug exposure of less than 3%.9 The systemic exposure depends not 
only on the adequacy of the isolation of the limb during the perfusion, but is also 
related to the systemic exposure to the perfused agent during reperfusion.58 
Although the limb is flushed after the perfusion, residual active agents still remain 
in the limb within the intravascular space or in the interstitial fluid, which results 
in a systemic peak of drug concentration following the re-establishment of normal 
vascular flow to the extremity. Systemic leakage of melphalan might cause mild 
nausea, bone marrow depletion, and fever. In case of leakage over 10% patients 
should have their white blood counts measured 7 to 14 days post-operatively to 
monitor bone marrow depression.  
TNFα might induce secondary host mediators in contrast to the other drugs used 
in the perfusion setting.59 The most serious complication after TNFα perfusion is 
the systemic inflammatory response syndrome (SIRS) accompanied by fever, rise 
in cardiac output, fall in systemic vascular resistance and the need for fluid 
resuscitation and inotropes. If leakage exceeded the 2% limit during perfusion, 
there was less exposure of the tumor bearing limb to TNF and an increased 
exposure of the patient systemic circulation to TNFα, resulting in more systemic 
side effects.58 There is a direct correlation between maximum TNFα concentrations _____________________________________________________________ 
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and systemic vascular resistance and cardiac index.60,61  Severe toxicity might be 
encountered over a leakage of 5%.18 In contrast Stam et al observed only a mild 
postoperative toxicity in the event of a significant leakage during perfusion.62 The 
more experience is achieved with the so called TNFα -perfusions, the better the 
transient, systemic side effects could be managed during the perfusion and 
postoperatively with appropriate resuscitative techniques. The leakage should not 
extend 10% (as per licensee). Currently SIRS is only seldom seen, since all the 
institutions performing TNFα perfusions are experienced, achieve less leakage 
rates and use extensive washout procedure at the end of the perfusion procedure, 
to reduce the release of TNFα from the perfused limb to the main circulation after 
restoration of the limb circulation.  
The normal tissues in the limb, skin, subcutaneous tissue, muscle, nerves, blood 
vessels, bone, and cartilage are all exposed to the same concentrations of cytostatic 
agents active against the tumor. Wieberdink developed a regional toxicity scoring 
system.15  The effects of the perfusate on normal tissues varied widely between 
individuals. Melphalan may cause skin toxicity, erythema and blistering, and 
serves as a document of the distribution of the perfusion.63 When a lymph node 
dissection is performed together with the perfusion, edema of the involved limb 
might be encountered. The most important toxicity is related to muscle and nerve 
damage, which might be avoided by a prophylactic fasciotomy, preventing the 
development of a compartment syndrome.64 All patients undergo some degree of 
skin reaction and lymph edema TNFα after the perfusion. This resolves in general 
within a month regarding the accompanied procedures, e.g. tumor resection 
and/or radiation. The Rotterdam perfusion group documented functional 
impairment of 20% of the upper limb and 36% of the lower limb after melphalan 
perfusion.64 In contrast Olieman and co workers showed no impairment of limb 
function after melphalan perfusion for melanoma compared to the unperfused 
limb.65 It might be expected that small proportion of patients (5-8%) undergoing a 
limb perfusion for melanoma will have long-term limb symptoms, without severe 
impairment, secondary to their perfusion treatment.66 After perfusion for locally 
advanced sarcoma impairment of limb function is not related to the perfusion, but 
to the extend of the surgical resection of the soft tissue mass and eventually 
adjuvant irradiation. Another risk factor in isolated regional perfusion is not 
related to the cytostatic agents, but to the (elderly) patients’ vascular status and the ________________________________________                    C h a p t e r  I I 
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extent of the soft tissue mass in case of perfusion for a locally advanced soft tissue 
sarcoma. Manipulation, cannulation and tight occlusion of sclerotic vessels might 
cause embolic events, arterial stricture after vessel repair, or arterial thrombosis, 
requiring reoperation or even amputation of the perfused limb. Beside the arterial 
complications, from the venous side deep venous thrombosis is sometimes 
encountered due to cannulation of the vein or the thrombogenic side effect induced 
by melphalan. Increase in limb temperature might slightly increase limb toxicity in 
melphalan perfusions. The addition of TNFα will significantly increase the limb 
toxicity due to increase of melphalan into the tissues and not to microembolization 
of tumor cells.67,68  
 
  Summary 
 
Isolated limb perfusion has the potential to the deliver high doses of 
chemotherapeutic agents to a tumor-bearing limb. There is no evidence-based 
indication for adjuvant isolated limb perfusions for high-risk limb melanoma, in 
contrast to therapeutic perfusions for extensive local recurrences or intransit 
metastases. The introduction of TNFα in combination of melphalan redefined the 
indication for therapeutic and palliative isolated limb perfusions in the limb saving 
treatment of locally melanoma and sarcoma of the limb, as well as multifocal skin 
cancers and drug-resistance bony sarcomas. The currently most widely used drugs 
in the perfusion setting are melphalan with or without TNFα.  
Various aspects of isolated limb perfusion treatment need to be further explored. 
The future developments in regional perfusion research should focus on new 
therapeutic perfusion agents and/or increasing the tumor sensitivity for TNFα 
without decreasing tumor response, as well as the further exploration of new 
anatomical areas in the body for regional cancer treatment, such the liver, lung, 
kidney and pelvis. _____________________________________________________________ 
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  Introduction 
 
Hyperthermic isolated regional perfusion of the limb (ILP) is a technique which 
has the possibility to deliver high concentrations of chemotherapeutic agents to an 
extremity, whereas only low drug concentrates are reached in the systemic 
circulation. Since Luck introduced melphalan (L-phenylalanine mustard) in 1956 as 
an active agent to inhibit growth of malignant melanoma in mice, it has been the 
preferred agent in ILP for intransit metastases of melanoma.1 Although ILP with 
melphalan is effective in the treatment of the patients with intransit metastases of 
melanoma, with a complete response rate of 50%, it has no effect in the adjuvant 
setting.2-4 Newer drugs which might be more effective than melphalan in the 
treatment of melanoma by ILP have therefore been sought. Cisplatin is one of the 
most active drugs in cancer treatment, however it has serious dose-limiting toxicity 
such as neuro-, nephro-, and ototoxicity.5 Therefore ILP with cisplatin was 
evaluated as an alternative to overcome these limitations of systemic treatment in 
the treatment of recurrent melanoma of the limb. However the  effectiveness of 
cisplatin in the so called therapeutic perfusion setting and for local control of 
tumor growth for the treatment of locally advanced melanoma and sarcoma of the 
extremities with delayed excision is not impressive.6-10 And the local neurological 
side effects of ILP with cisplatin in the perfused limb are still present in the form of 
a irreversible peripheral sensory and motor neuropathy.7 Therefore in several 
institutions cisplatin was abandoned as a cytostatic agent in the perfusion setting. 
There are however several other institutions that still use and advocate cisplatin in 
ILP.11-13 Carboplatin is a second generation platinum analogue with similar efficacy 
in most tumors but with less neuro-, oto- and nephrotoxicity when compared to 
cisplatin when applied systemically.14,15 A feasibility study was initiated to study 
the effect of carboplatin, as an agent for ILP with respect to the local tumoricidal 
effect, as well as the local treatment morbidity. 
  
  Patients and Methods 
 
Between November 1991 and February 1993 two patients (patient 1 and patient 2) 
with locally advanced recurrent and intransit metastases of melanoma of the lower ________________________________________                 C h a p t e r  I I I 
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limb (Stage IIIA, MD Anderson staging) and one patient (patient 3) with a locally 
advanced primary irresectable soft tissue sarcoma of the lower limb participated in 
a feasibility study of ILP with carboplatin. None of the patients had distant 
metastases at time of the perfusion. Patients were treated with intent of preserving 
the affected extremity. The maximum follow up period was 95 months. Patient 
data are summarized in Table 1. Since the systemic dosage of carboplatin used 
clinically is 4 times the cisplatin dosage, a fourfold higher dose compared to 
cisplatin was used for the limb perfusion.5,16 Based upon an earlier dose finding 
study where a maximum dose of cisplatin of 30 mg/L limb volume was used in 
ILP, an initial carboplatin dosage was chosen of 125 mg/L limb volume.7,9 
 
 
Patient 
No. 
 
Age 
(yrs)/
Sex 
 
Tumor type 
and staging* 
 
Previous 
therapy 
 
Perfusion 
level 
 
Limb 
vol (l) 
 
Total 
carboplatin  
in mg 
 
1 
 
57/F 
 
melanoma 
stage IIIA 
 
tumor 
excision + 
ILP with 
melphalan + 
actinomycin- 
D 
 
popliteal 
 
5.1 
 
625 mg 
 
2 
 
72/M 
 
melanoma 
stage IIIA 
 
tumor 
excision 
 
femoral 
 
12 
 
1500 mg 
 
3 
 
52/M 
 
low grade 
myxoid 
liposarcoma 
 
None 
 
iliacal 
 
13 
 
1625 mg 
M = male, F = female; *Staging according to M.D. Anderson staging system    
 
Table 1: Patient characteristics, perfusion characteristics and carboplatin dosage _____________________________________________________________ 
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All patients had normal pre-operative kidney function. To prevent postoperative 
renal failure due to systemic leakage, hyperhydration was started one day before 
ILP and was continued up to 5 days postoperatively. Hyperhydration consisted 
out of 2 l 0.9% NaCl intravenously superfluous to the patients’ habitual fluid 
intake. The perfusion technique used at the Groningen University Hospital is 
based on the technique developed by Creech et al.17 All patients were operated 
under general anaesthesia. After a skin incision, the iliac, femoral or popliteal 
vessels were exposed and collateral vessels were clipped. The patients were 
heparinized (3.3mg/kg body weight) and catheters were inserted in the artery and 
vein, and both were connected to an extracorporeal circuit. The extremity was 
completely isolated from the central circulation with the aid of an Esmarch 
bandage. The perfusate consisted out of 250 ml red blood cell concentrate, 250 ml 
Isodex® (NPBI, Emmer-Compascuum, The Netherlands) in 0.9% NaCl, 30 ml 
NaHCO3 8.4% and 25 mg heparine (2500 IU) (Braun Melsunger AG, Melsunger, 
Germany). Leakage to the systemic circulation was assessed by injecting I131-
albumin into the isolated circulation and continuously monitoring of radioactivity 
was performed by means of a NAC-scintillation detector, which was placed over 
the heart.18 The leakage was indicated by extent of cross circulation between the 
perfused extremity and the circulation in the rest of the body. All perfusions were 
performed under mild hyperthermic conditions (39 - 40°C). If the muscle 
temperature had reached a temperature of 38°C and after leakage to the systemic 
circulation was excluded, the carboplatin 125 mg/L limb volume (Bristol Myers 
Squibb Company, Woerden, The Netherlands) was administered to the perfusate 
over a 10 min period. The flow rate of the perfusion fluid in the perfusion circuit 
was approximately 500 ml/min. After 1 hour of perfusion, the extremity was 
flushed with 500 ml Isodex® in 0.9% NaCl and 250 ml red blood cell concentrate. 
Both catheters were removed and the vessels were repaired. The heparin was then 
neutralized with protamine sulfate and a fasciotomy was performed to prevent a 
compartment syndrome. Before and during the perfusion, 10 ml perfusate samples 
were collected at 10 min intervals to determine the ultrafiltrated platinum (fPt) 
levels as previously extensively published.19 The leakage into the systemic 
circulation was also determined by measuring the patients fPt plasma 
concentrations at the end of each perfusion procedure both before and after 
restoration of the circulation to the perfused limb and during the 7 days following ________________________________________                 C h a p t e r  I I I 
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the perfusion. For fPt perfusate elimination kinetics, data were subjected to 
logarithmic regression analysis (concentration = A.e-k.t). The areas under the 
concentration vs. time curves (AUC) were calculated using the model independent 
trapezoidal rule and covers the perfusion period (t = 0 - 60 min).20 Tissue biopsies 
were taken for fPt determination in both melanoma patients at the end of the ILP, 
when the normal limb circulation was restored.    
All three patients were followed up post operatively by history, physical 
examination, and routine blood counts and blood chemistry analysis were 
performed on a daily basis on days 1 - 7, and 14 and 21 days postoperatively. Total 
serum protein and albumin was controlled one day preoperatively and 
postoperatively. Six weeks after perfusion electrodiagnostic evaluations 
(electromyogram (EMG) and nerve conduction study) were performed to 
investigate nerve toxicity of the carboplatin perfusion in patients 1 and 3. 
Unfortunately patient 2 refused the neurological examination. The local limb 
perfusion toxicity was graded according to the criteria decribed by Wieberdink et 
al.21 Eight weeks after perfusion, patient 3 was readmitted for a so called delayed 
resection of a locally advanced soft tissue sarcoma of the lower limb. The study 
was approved by the local Medical Ethical Committee of the Groningen University 
Hospital and all patients gave informed consent.  
 
  Results 
 
All three perfusions could be performed under standard perfusion conditions with 
minimal I131-albumin leakage (0-5%) (Table 2) and without any acute systemic 
toxicity or morbidity. The local toxicity consisted in all 3 patients of a grade II 
toxicity of the perfused limb which is characterized by erythema, edema or loss of 
sensation which resolved spontaneously in all patients.21 Patient 2 developed an 
abscess in the groin area of the perfused limb 3 weeks after the femoral perfusion 
with superficial inguinal node dissection. Except for a marked decrease in total 
serum protein and albumin 1 day postoperatively, there were no major 
biochemical changes or myelosuppression. The total serum protein decreased from 
a mean of 67.3 + 2.5 g/L preoperatively to 47.7 + 4.5 g/L (P<0.04 paired Student’s t-
test) one day postoperatively. Serum albumin decreased from a mean of 46.3 + 4.2  
 _____________________________________________________________ 
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Patient 
No. 
 
Leakage 
(%) 
 
Toxicity 
grade* 
 
Clinical signs of 
neuropathy 
 
Electrodiagnostic 
evaluation (EMG + 
nerve conduction) 
 
1 
 
1.8 
 
II 
 
yes 
 
Sensory + Motor 
neuropathy 
 
2 
 
0 
 
II 
 
yes 
 
nd 
 
3 
 
5 
 
II 
 
yes 
 
Sensory + Motor 
neuropathy 
nd = not determined; *Toxicity grade according to Wieberdink et al.21 
 
Table 2: Leakage, toxicity and neurological follow up 
 
g/L preoperatively to 32.0 + 4.0 g/L (P<0.002 paired Student’s t-test) one day 
postoperatively. This resulted in the development of edema in the perfused limb 
postoperatively for which intravenous albumin was administered postoperatively 
in all three patients to correct the serum albumin. Physical examination of the first 
two patients, both melanoma intransit metastases, revealed clinically a complete 
response making delayed excision unnecessary. A CT scan of the liposarcoma of 
patient 3 showed a 25% reduction of the tumor size which allowed a complete 
macroscopical marginal resection after 8 weeks. However microscopically vital 
tumor was observed in at least 50% of the resected material with focal necrosis. The 
patient received adjuvant radiation therapy (60 Gy) at the primary tumor site, 
which was well tolerated. Clinically all 3 patients showed signs of sensory and 
motor neuropathy in the perfused limb. Electrodiagnostic evaluations were 
performed in order to assess the local neurotoxicity of the carboplatin in patients 1 
and 3. Patient 1 was tested both pre- and postoperatively because this patient 
underwent an ILP with melphalan of the same limb one year previously. 
Preoperative nerve conduction velocities of the perfused left leg (peroneal nerve, F ________________________________________                 C h a p t e r  I I I 
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response, H reflex) were all slightly slower then on the right side. The sensory 
sural nerve amplitude was also lower on the left side (left 4µV, right 16µV). The 
control EMG and nerve conduction study postoperatively showed a further 
decrease in the conduction velocity of the peroneal nerve and the amplitude from 
the sural nerve decreased by 2µV. The postoperative EMG and nerve conduction 
study of patient 3 revealed that the right (perfused limb) extensor hallucis muscle 
and abductor hallucis muscle showed partial denervation, and the sural nerve also 
showed a lower amplitude compared with the left leg.  
In all three patients the affected limb could be preserved. After a complete initial 
clinical response to the perfusion, patient 1 developed local recurrences over the 
next few years and the first being within 1 year postperfusion. All of these local 
recurrences and intransit metastases were treated by local excision only. This 
patient is still alive 95+ months after perfusion with carboplatin. Patient 2 also 
showed a complete initial clinical response but within 1.5 year a local recurrence 
appeared at the primary tumor site which was excised. This patient went on to 
develop lung metastases 44 months after perfusion and died 56 months after 
perfusion. Patient 3 did not develop a local recurrence after radiation therapy but 
died from lung metastases 31 months after perfusion.  Systemic plasma 
concentrations of fPt, determined at the end of perfusion before restoration of the 
normal circulation, were also found to be relatively low (<0.1 - 0.98 mg/L). Systemic 
plasma fPt concentrations remained negligible in all patients during the 7 days 
following the perfusion. Perfusion data and pharmacokinetic parameters are 
summarized in Table 1 and Table 3. Concentrations of fPt in tissue biopsies, taken 
from patients 1 and 2 of the skin and the anterior tibial muscle at the anterolateral 
part of the lower extremity during the fasciotomy after ILP, showed a great 
variation in concentration between the skin and muscle, with especially high fPt 
concentrations in the skin. In patients 1 and 2 the concentrations in the skin were 
respectively 27.6 ug fPt g-1 tissue and 25.0 ug fPt g-1 tissue compared to the 
concentrations in the muscle which were respectively 9.0 ug fPt g-1 tissue and 7.6 
ug fPt g-1 tissue. _____________________________________________________________ 
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Patient 
 
t½ 
(min) 
 
Cmax 
(mg/L) 
 
Ct = 60 
(mg/L) 
 
AUC 
((mg/L)/min) 
 
systemic fPt 
concentration 
(mg/L) 
 
1 
 
104 
 
488 
 
344 
 
24070 
 
<0.1 
 
2 
 
30 
 
824 
 
113 
 
9995 
 
0.98 
 
3 
 
50 
 
620 
 
250 
 
20378 
 
<0.1 
 
Table 3: Pharmacokinetic parameters of fPt in the perfusate during 60 min ILP with 125 
mg/L carboplatin extremity (assuming first order kinetics) and systemic fPt concentration 
after 60 min ILP. 
 
  Discussion 
 
Regional isolation perfusion was introduced to deliver large doses of cytotoxic 
drugs to the local tumor area while avoiding systemic toxicity. Melphalan is still 
the most frequently used antitumor drug in ILP for melanoma.6,8,22,23 Even with a 
high remission rate (80%), a great deal (50%) of the melanoma patients fail to 
achieve a durable complete response.2,3,23 Therefore a search was initiated for 
alternative drugs or the application of combination of agents to be used in ILP. 
Several cytostatic agents have been used besides melphalan, such as actinomycin D 
and DTIC (imidazole carboxamide). The feasibility of cisplatin in ILP has also 
previously been investigated by several institutions, but with conflicting results. 
Some authors claim that the local severe toxicity and the equal or less effectiveness 
does not justify the use of cisplatin.6-10 But there are also other institutions that still 
use and advocate the use of cisplatin in ILP.11-13 Carboplatin, a second generation 
platinum compound, was attractive for clinical use because of its reduced nephro-, 
neuro-, and ototoxicity than cisplatin when administered systemically.24 It differs 
in the molecular structure from cisplatin by replacing the two cis chloride atoms by ________________________________________                 C h a p t e r  I I I 
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a cyclobutane dicarboxylate molecule.5 Platinum co-ordination complexes inhibit 
tumor growth by their effects on DNA replication. Once bifunctionally bound to 
DNA, the mode of action of carboplatin is not different from cisplatin, but the 
platinum induced DNA lesions (DNA interstrand cross links) are formed at a 
slower rate with carboplatin compared to cisplatin.16 Our clinical results show that 
application of carboplatin in ILP led to the development of, or an increase in the 
neuropathy in the perfused limbs of all three patients. In two patients this was 
confirmed by electrodiagnostic evaluation. Patient 1 already showed clinical signs 
of neuropathy in the affected limb which was confirmed by EMG and nerve 
conduction study prior to the carboplatin perfusion. This neuropathy was probably 
due to the previous perfusion with melphalan. The postoperative tests after the 
carboplatin perfusion of this patient showed no apparent denervation potentials, 
but increased disturbances in the motor and sensory conduction velocities 
compared to the first neurological tests were observed. Patient 2 and 3 had no 
clinical signs of a neuropathy preoperatively. However, the postoperative 
electrodiagnostic findings of patient 3 did show a new development of a 
neuropathy distally in the perfused limb. With the limitations of the small number 
of patients treated in this feasibility study it should be noted that with respect to 
the locoregional tumor control, the treatment regimen did not appear to be 
promising. Both melanoma patients who underwent perfusion with carboplatin 
developed local recurrency and/or intransit metastases within 1￿ year after 
perfusion, and histologically 50% vital tumor was still observed after excision of 
the sarcoma from patient 3.  
There has only been one case report and one study in which carboplatin has been 
used for isolated limb perfusion. Nakayama et al. reported minimal side effects 
after perfusing 1 patient with 450 mg carboplatin for melanoma of the lower limb.25 
They found a complete clinical and histologic response of the tumor and in their 
follow up period of 10 months, no local recurrency was observed. This is in 
concordance with the findings of Ariyan et al. who performed ILP on 20 patients 
with carboplatin (400 mg/m2 body surface area) and the results were found to be 
effective and with very low toxicity with a median follow up of 25 months.11 Both 
studies however do not report on observed local neurotoxicity. In our study the 
carboplatin dosage was calculated on the limb volume and not on the body surface 
area,  thus leading to a much larger carboplatin dosis administered (up to 4 times _____________________________________________________________ 
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as much). This could possibly explain the enhanced neurotoxicity seen in this 
series. 
Next to the search for new agents for ILP, different combinations of drugs are 
being investigated. The combination of tumor necrosis factor α (TNFα) and 
melphalan has been used for the local perfusion of recurrent melanoma of the 
limbs and for extremity sarcomas.26-31 Lienard et al. reported that the complete 
response rate for melanoma metastases increased to 80 - 90% after the addition of 
TNFα to the perfusate, but with an increased risk of side effects.31 The median 
disease free interval time did not increase with the addition of TNFα, making 
monotherapy with melphalan currently the  drug of choice for ILP in melanoma.23 
For soft tissue sarcomas of the limbs the combination of TNFα and melphalan as 
perfusion agents has been proven to be effective in salvaging the affected 
limbs.27,28,30 Results from a recent international multicenter study, showed that in 
246 patients with irresectable soft tissue sarcoma a complete response rate of 28%, 
a partial response rate of 47% and 17% no change after perfusion with TNFα and 
melphalan was observed. Enabling delayed excision and preserving the extremity 
in a substantial number (71%) of perfused patients.32 
A combination of TNFα and cisplatin has been investigated by Bartlett et al. in 
peritoneal perfusion in the treatment of peritoneal carcinomatosis.33 The results 
were disappointing because of an increased nephrotoxicity compared to cisplatin 
alone, rendering it unfeasible. A canine experimental study by van Ginkel et al. 
also combined the drugs cisplatin and TNFα in ILP and tested this regimen 6 
healthy dogs.34 They observed an increased toxicity compared to ILP with cisplatin 
alone. Despite a sublethal systemic concentration of TNFα that leaked from the 
perfusion circuit, 3 dogs died within 24 hours of ILP. Another dog developed a 
necrotic limb which the authors explained as an enhanced cytotoxic effect of 
cisplatin to the local tissues due to the addition of TNFα. Taking into account the 
before mentioned results between cisplatin and TNFα and considering the 
similarity between cisplatin and carboplatin, we do not warrant further 
investigation into the feasibility of the combination between carboplatin and 
TNFα. 
 
The local neurotoxicity observed with ILP makes carboplatin an unattractive 
alternative agent for ILP. However, compared to the before mentioned studies of ________________________________________                 C h a p t e r  I I I 
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Nakayama25 and Ariyan11 the patients in this study received a higher dose of 
carboplatin which could account for the observed neurotoxicity. _____________________________________________________________ 
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  Introduction 
 
With hyperthermic isolated limb perfusion (ILP), high doses of cytotoxic agents 
can be administered locally in a limb without systemic toxicity. This method was 
introduced in 1958 by Creech and Krementz and has since undergone many 
improvements such as the addition of hyperthermia.1,2 ILP is employed mostly in 
the treatment of recurrent melanomas and locally advanced extremity soft tissue 
sarcomas (STS). Since Luck introduced the cytostatic agent L-phenylalanine 
(melphalan) in 1956, it has been the preferred agent in ILP for intransit metastases 
of melanoma.3 Because the dosage of the chemotherapeutic agent is high (up to 15–
20 times the systemic tolerated dose), a considerable risk of toxic effects due to 
leakage of the perfusate to the systemic circulation may occur.4 Leakage of more 
than 15% perfusate containing melphalan into the systemic circulation may cause 
toxic effects such as bone marrow depression, gastro-intestinal toxicity, hair loss 
and pruritis.5-7 With the introduction of recombinant tumor necrosis factor α 
(TNFα) in the early nineties, the effectiveness of the ILP was increased for 
melanoma and especially for STS patients.8,9 However, leakage of TNFα into the 
systemic circulation gives rise to more severe side effects than melphalan alone. A 
1% leakage may already result in hypotension of the patient and a 10% leakage of 
TNFα can cause a potentially fatal septic shock like syndrome.10,11 However, strict 
isolation of the limb is not always achievable due to anatomical variations and/or 
technical reasons. Minimal systemic leakage can therefore not always be 
prevented, and makes continuous leakage monitoring during the perfusion 
procedure of utmost importance. Recently many methods of leakage detection 
methods have been described in the literature ranging from intermittent blood 
sampling to continuous external monitoring using radio-isotopes.  
At the Groningen University Hospital continuous external leakage measurement is 
performed using 131I-albumin as the radio-isotope. Between 1977 and 1991 the 
median of the maximum percentage leakage was reported to be 8.0% in this 
institution.7 Since that period there have been a number of improvements in the 
ILP technique and in leakage monitoring. We therefore embarked on a 
retrospective study to analyze the maximum leakage of the patients who 
underwent ILP in the period between 1991 and 2000. 
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  Patients and Methods 
 
Between January 1991 and March 2000, 119 patients underwent a limb perfusion at 
the University Hospital Groningen. Of the 119 perfusions, 67 were iliacal (56%), 12 
femoral (10%), 25 popliteal (21%) and 15 axillary (13%) perfusions. The perfusion 
was carried out on 71 female (60 %) and 48 male patients (40%) with a median age 
of 56 (range 17-79) years (Fig. 1). Sixty-two patients (52%) were perfused for 
intransit melanomas, 51 patients (43%) for a primarily unresectable sarcoma and 6 
patients (5%) had other types of malignancies (Fig. 2). Patient, tumor and treatment 
data was retrieved from the Groningen melanoma and sarcoma databases.  
 
Perfusion Technique 
The perfusion technique used at the Groningen University Hospital is based on the 
technique developed by Creech et al and has extensively been described before by 
Schraffordt Koops et al.1,12 The surgical technique of the ILP between the two time 
periods remained the same. All patients were operated under general anesthesia. 
After a skin incision, the iliac, femoral, popliteal or axillary vessels were exposed 
and collateral vessels were clipped. In iliacal perfusions the hypogastric vessels 
were also temporarily closed. The patients were heparinized (3.3mg/kg body 
weight) and catheters were inserted in the artery and vein, and both were 
connected to an extracorporeal circuit. The extremity was isolated from the central 
circulation with the aid of an Esmarch bandage. The perfusate consisted of 250 ml 
red blood cell concentrate, 250 ml Isodex® (NPBI, Emmer-Compascuum, The 
Netherlands) in 0.9% NaCl, 30 ml NaHCO3 8.4% and 25 mg heparin (2500 IU) 
(B.Braun Melsungen AG, Melsungen, Germany). All perfusions were performed 
under mild hyperthermic conditions (39 - 40°C). If the muscle temperature had 
reached a temperature of 38°C and if almost no leakage to the systemic circulation 
was detected, the chemotherapeutic agents were directly added to the perfusion 
circuit via the arterial line. Especially for the TNFα perfusions an almost 0% 
leakage was required before the TNFα was added to the perfusion circuit. For the 
less toxic melphalan, a leakage of 5% was generally accepted. mg/l upper limb 
volume (Alkeran, Glaxo Wellcome, London, Great Britain).  If TNFα was used 
(Boehringer Ingelheim International GMbH, Ingelheim am Rhein, Germany), the  _____________________________________________________________  
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Fig. 1 Age distribution of all 119 perfused patients 
 
dosage was 4 mg for the lower extremity and 3mg for the upper extremity (given 
30 min before the melphalan).The dosage used in melphalan perfusions is 10 mg/l 
lower limb volume and 13 The flow rate of the perfusion fluid in the perfusion 
circuit was approximately 500 ml/min. After 1 hour for non TNFα perfusions and 
90 min for TNFα plus melphalan perfusions, the extremity was flushed with 
Isodex® in 0.9% NaCl (between 3-6L depending on the level of perfusion) and 250 
ml red blood cell concentrate. Both catheters were removed and the vessels were 
repaired. The heparin was then neutralized using protamine sulfate and a 
fasciotomy was performed to prevent a compartment syndrome. If required, a 
local excision of the melanoma and intransit metastases was performed after the 
perfusion and, if necessary a free skin graft from the other limb was taken and kept 
under sterile conditions at 4 degrees Celsius and placed on the wound 3 days later. 
Post ILP patients were admitted to the intensive care unit for 24 hours in order to 
monitor clinical toxicity from the TNFα and/or melphalan.   
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Fig. 2 Tumor types corresponding to gender 
 
Leakage Monitoring 
Leakage measurement took place with the help of radioactive tracers. A low dose 
of 131I-albumin (0.5 MBq) and a dose of 99mTc-albumin (10 MBq) were administered 
to the systemic circulation. A tenfold higher dose of 131I-albumin (5 MBq) was 
administered to the isolated limb circulation. A fixed scintillation detector placed 
above the heart measured the radioactivity over the cardiac zone. The count rate of 
131I-albumin at the start of the perfusion (t=0) was the setpoint used for calculating 
the leakage percentage of the cytotoxic drugs. Leakage from the perfused limb to 
the systemic circulation results in an increase of this count rate. This increase, 
corrected for the blood volume ratio and the radioactivity ratio in both 
compartments, was a direct measure of percentage leakage. These changes were 
automatically converted by a microprocessor connected to the detector into 
percentages of leakage. Radioactivity was continuously registered during the 
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procedure (fig. 3). The 99mTc-albumin baseline radioactivity was used as a control 
for the detector efficacy during the whole procedure. To avoid detrimental effects 
by the radioactive 131I to the thyroid gland, the patient was given iodine (15 drops 
of Lugol solution twice daily) 1 day before the operation.       
 
Statistics 
The software package SPSS 9.0 for Windows (SPSS, Inc., Chicago IL) was used for 
statistical analysis. The maximum leakage is defined as the zenith of the leakage 
that occurred during perfusion in each patient. For descriptive statistics the median 
value of the maximal leakage was documented. The Mann Whitney U test was 
used for comparison of the differences in maximum leakage between the various 
subgroups. 
 
  Results 
 
All perfusions were performed under standard perfusion conditions. There was no 
mortality related to the perfusions. For all 119 patients the median value of the 
maximum leakage (leakagemax) was 2.7% (range 0-21.0%). There was no statistical 
difference in leakagemax between male (2.4%, range 0-21.0%) and female (3.0%, 
range 0-12.0%) patients. Nor was there a statistical significant difference in 
leakagemax between the various age groups. However, a statistical difference of the 
leakage was detected between the levels of perfusion. Iliacal and femoral 
perfusions had significant higher leakagemax than popliteal and axillary perfusions. 
For iliacal perfusions the leakagemax was 4.5% (0-21.0%), for femoral perfusions 
3.8% (0-15.5%), for popliteal perfusions 1% (0-9.0%) and for axillary perfusions 0% 
(0-4.0%) (Fig. 4). The leakagemax for the groups stratified for the different drugs 
used also showed a statistical significant difference. When TNFα was used, a lower 
leakagemax was detected compared to when no TNFα was used: median 2.0% (0-
15.5%) for the TNFα-group and 4.0% (0-21.0%) for the non-TNFα group (P<0.05). 
However, there was no difference in morbidity between the patients who where 
perfused with TNFα and those who were not. The fasciotomy and melanoma 
excision wounds created post ILP usually healed without any major complications.  
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Fig. 3 Continuous leakage monitoring during isolated limb perfusion with a scintillation 
detector placed above the heart (with permission of Hoekstra et al. Continuous leakage 
monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques 
and results. Regional Cancer Treatment 1992; 4:301-304. Springer Verlag) 
 
 
  Discussion 
 
Creech and Krementz introduced regional isolation perfusion in 1958 as a method 
to deliver large doses of cytotoxic drugs to the local tumor area while avoiding 
systemic toxicity.1 Monitoring of leakage occurring during regional perfusion of 
the isolated circuit into the systemic circulation has generally been mandatory due  
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Fig. 4 Distribution of the maximum leakage and the amount of perfusions corresponding to 
the level of perfusion (dotted line represents the median value) 
 
to dose escalation of the chemotherapeutics in the perfusate to levels which would 
be extremely morbid or lethal if given systemically. Several leakage detection 
methods are described in the literature. Many groups have monitored the systemic 
levels of the drug used exclusively through the analysis of intermittent blood 
samples.13,14 The flaw in this method is however, that the monitoring is not 
continuous, and the results take at least 20 minutes before they are known. The 
surgeon has therefore no possibility for acute intervention if a potentially 
dangerous amount of leakage of the perfusate is being monitored. A search was 
therefore initiated for a continuous, real-time method of monitoring. Stehlin was 
the first to describe a continuous method in as early as 1961 using the radioactive 
isotope  131I-albumin.15 I n  1 9 8 9  a  h a n d  h e l d  g a m m a  d e t e c t o r  w a s  i n t r o d u c e d  b y  
Sardi to be placed between the thighs and precordially in order to record the 
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radioactivity of the 131I-albumin that had leaked into the systemic circulation.16 
However, measurement of the leakage with the handheld detector is accompanied 
by a method-error, because slight variation in probe positioning gives rise to 
altered results. Nowadays when a toxic drug like TNFα is being used, accurate 
leakage measurement is of the utmost importance, since a 1% of TNFα leakage can 
cause hypotension and a 10% leakage can cause a potentially fatal septic shock like 
syndrome.10,11 With the establishment of a stationary scintillation detector placed 
above the heart, the before mentioned method-error was eliminated.17 
Despite available detection methods, the data or leakage of the perfusate to the 
systemic circulation is rarely mentioned in the literature. In a previous article 
covering the period from 1977 until 1990 at this institution, a median of the 
maximum leakage of 8.0% (range 0-30%) was reported, with an achieved leakage 
of less than 15% in 84% of the patients.7 During this period the drug of choice was 
melphalan, and a maximum leakage of 15% of melphalan did not prove to cause 
systemic toxicity.6 Nevertheless, this median leakage is considered being too high 
for the currently used treatment schemes which include TNFα. In this period from 
1977 – 1990 there was constant experimenting going on with new leakage 
techniques in order to achieve a minimal leakage. From 1977 – 1982 the perfusions 
were performed with a low flow rate of 100-150 ml/min with a mean leakage of 
7.04 ± 1.04%. On the basis of Fontijne’s study a more physiological perfusion was 
implemented since 1982, and the perfusion pressure was derived from the patients’ 
arterial and venous pressure during the operation.18 This resulted in an increase in 
flow rate ranging between 500-900 ml/min. However, this was accompanied with a 
significant higher mean leakage: 10.43 ± 1.82% (P<0.001). To reduce complications 
of this increased leakage, the cytotoxic drugs have since 1987 been administered 
only when the observed leakage is less than 5% over a period of 5 minutes. 
Consequently, this resulted in a statistically different decrease in leakage to 7.35 ± 
0.69% (P<0.001) in patients who were actually perfused with the cytotoxic drugs. 
When the TNFα perfusions were introduced in the early nineties, no leakage of the 
perfusion circuit to the systemic circulation was accepted in contrast to the 
melphalan perfusions. In the current series starting from 1991 the overall median 
of the maximum leakage was calculated at 2.7% (range 0-21%). This is significantly 
lower than the period 1977 – 1990 (P<0.05). This difference is according to us based 
on three aspects. First of all, the previous report is based on 331 iliacal and 55 _____________________________________________________________  
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femoral perfusions and the current series includes 40 axillary and popliteal 
perfusions from the 119 total perfusions. Univariate analysis showed that the level 
of isolation is a factor predicative of systemic leakage where the iliacal and femoral 
levels of isolation had a significant higher chance of leakage than the popliteal and 
axillary levels of isolation. This aspect has been highlighted before in the literature 
for which Pace described an optimal method for isolation at the iliac level.19 His 
method was to temporary close the common iliac vein during perfusion, for which 
a mean leakage of 9% was reported. In the Groningen iliacal perfusion technique 
the external iliac, obturator, hypogastric and the collateral veins are temporary 
closed.12 Secondly, since the early nineties, the very toxic cytokine TNFα is 
increasingly being used in the perfusion setting since it has been proven to be very 
effective in limb salvaging for STS.8,20 These cases involve delivery of TNFα levels 
to the tumor that are approximately 15-20 times the maximally tolerated systemic 
levels.4 If there is significant leakage (over 10%), the resultant systemic 
complications could be fatal. However, Stam et al. recently published a report in 
which a leakage of up to 65% TNFα into the systemic circulation only caused a 
hypotension which was easily corrected with either fluid administration or 
dopamine treatment for 2 days.21 Interestingly, since the introduction of TNFα 
there has been a significant decrease in leakage compared to when melphalan is 
used alone (P<0.05). It is our opinion that this decrease in leakage is based upon the 
surgeons and perfusionists awareness of the added risk of TNFα and not based 
upon the pharmacokinetics of TNFα.  
The third reason for a decrease in leakage is attributed to the decrease in flow rate 
as described by Sorkin et al. in 1995.22 As mentioned before, since the early eighties 
at the Groningen institution a high flow rate was used according to Fontijne.18 But 
Sorkin observed a decrease in leakage from 12.5% to 2.3% when the flow rate was 
decreased from 869 ml/min to 286 ml/min. Moreover, Allen reported that a 20% 
decrease in flow rate will reduce the leakage from the extremity to the general 
circulation by 50%.23 This is a very important observation since a sufficient flow 
rate is required to maintain physiological blood gas values. But the flow rate 
should however not reach levels causing raised venous pressure which would 
subsequently lead to an increase in regional toxicity and increased systemic 
leakage. In our institution a flow rate between 400 and 500ml/min was therefore 
adapted for this purpose. Just recently a new technique has been implemented ________________________________________                  C h a p t e r  I V  
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where the flow rate is based on the limb volume and is expected to reduce the 
leakage even further. It is interesting to note that even though the leakage rate in 
the latter years has decreased, we did not notice a decrease in morbidity between 
the patients from the two time periods. If there is a substantial leakage, the order of 
events to minimize the leakage is as follows: First of all, the venous tourniquet is 
re-applied. If this does not result in a decrease of leakage the systemic pressure is 
increased to normal pressure values using dopamine and/or bringing the patient 
into a Trendelenburg position. If the leakage is still unacceptable, the flow rate is 
subsequently decreased. If the measures taken have no effect on minimizing the 
leakage, the procedure is terminated without perfusing the limb with the cytotoxic 
drugs. Klaase et al. reported in 1993 a cumulative systemic leakage of 0.9% (95% 
confidence interval) for their series of 438 perfusions performed at their 
institution.5 However, to our knowledge, their leakage detection method differed 
considerably to the one used in this institution. Their method consisted of a small 
systemic calibration dose and a higher limb dose of 99mTc-albumin to measure the 
leakage. This compared to our method where we use a small calibration dose of 131I 
-albumin and a higher dose of 131I-albumin for the limb. 131I-albumin has a longer 
half life than 99mTc-albumin (8 days compared to 6 hours respectively), which 
results in a longer circulation of the isotope in the systemic circulation and 
therefore enhances steady measurement.24 In our setting, the use of 99mTc-albumin 
serves as a control for correct measurement: because its registration is not leakage 
depended, the time-curve should display a decrease in radioactivity based on the 
half-life (t½) time of 99mTc-albumin. Should an unintentional displacement of the 
detector occur, then this is readily reflected in a deviation from the (t½) curve. 
When only 131I-albumin was used, such a displacement of the detector might be 
wrongly interpreted as a change in leakage.  
 
In summary, even under the most optimal conditions it is not always possible to 
achieve total limb isolation when perfusing at the iliacal or femoral level. Using our 
technique of monitoring, leakage is readily detected and seems to be superior to 
the technique using 99mTc-albumin alone. Nowadays the leakage from the isolated 
circuit into systemic circulation has significantly declined compared to the days 
when melphalan was the sole drug used. This is due to the increased awareness of 
surgeons for the very toxic TNFα, which has caused them to operate more _____________________________________________________________  
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cautiously. The flow rate regulation in the ILP circuit and optimal regulation of the 
systemic blood pressure have also been major contributors to this improvement. It 
is therefore possible to achieve a leakage rate of 5% or less.    ________________________________________                  C h a p t e r  I V  
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Editorial 
 
Isolated Limb Perfusion in the Management of 
Patients with Recurrent Limb Melanoma: An 
Important but Limited Role 
 
John F. Thompson and Johannes H. W. de Wilt 
 
  Isolated limb perfusion (ILP) was 
introduced into clinical practice in the 
mid-1950s, based on the same principles 
that had been applied to develop 
extracorporeal cardiopulmonary bypass a 
few years earlier. The concept was 
simple. By temporarily isolating the 
vasculature of a limb, high cytotoxic 
drug concentrations could be achieved 
without producing serious systemic side 
effects. Early studies using hyperthermic 
ILP with melphalan for limb melanoma 
produced impressive results, with overall 
response (OR) rates of around 80% and 
complete response (CR) rates for 
measurable limb disease of 30%–50%.
1
  
More recent reports indicate that CR 
rates exceeding 50% are now obtained in 
most melanoma treatment centers where 
ILP is undertaken.
2
 Even higher CR rates 
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when tumor necrosis factor (TNF) has 
been used with melphalan.
3
 Apart from 
the generally unacceptable option of 
amputation, no other form of treatment 
(systemic, regional, or local) achieves 
response rates that are consistently as 
high as those able to be obtained by ILP. 
It provides results far superior to those 
able to be achieved by any form of 
systemic chemotherapy, for example, 
where OR rates exceeding 20% are 
uncommon and CR rates rarely exceed 
1%–2%. However, despite the clearly 
demonstrated effectiveness of ILP for 
limb melanoma, it is a technique still 
used in only a small number of centers 
worldwide. The principal reason for this 
paradoxical situation is that, although the 
procedure is elegantly simple in concept, 
in practice it is a surgical tour-de-force – 
technically complex and demanding, 
labor intensive, time consuming, and 
costly. It has become clear that if ILP is 
to be effective and safe, meticulous 
attention to every aspect of the procedure 
is essential, with comprehensive 
monitoring of all parameters that might 
influence efficacy and outcome. These 
considerations have meant that the use of 
ILP, both for melanoma and soft tissue 
sarcoma, has been largely restricted to a ________________________________________                      E d i t o r i a l  
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few tertiary referral centers with 
appropriate academic staff and sufficient 
resources to undertake ILP as a clinical 
research endeavor. The control and 
monitoring of systemic drug leakage, as 
described in the paper by Daryanani et 
al.
4
  in this issue of Annals of Surgical 
Oncology, represents just one of the 
many technical challenges which must 
be overcome if ILP is to be performed 
with safety. Because of its complexity, 
cost, and potential morbidity, the 
objectives of ILP and the indications for 
its use must be very clearly understood. 
It was shown to have no effect 
whatsoever on survival in the large 
prospective EORTC-WHO-NAPG trial
5
 
comparing standard surgery plus 
adjuvant ILP with surgery alone for 
patients with melanomas ≥1.5 mm 
thickness. Nor has it ever been 
demonstrated to influence survival when 
used as a therapeutic procedure in the 
presence of macroscopic limb disease. 
ILP can nevertheless generate 
considerable morbidity, depending upon 
such factors as the type and dose of 
chemotherapeutic agents used, adequacy 
of oxygenation, level of hyperthermia, 
perfusate flow rate, and duration of 
perfusion. Potential complications, 
including damage to blood vessels, 
nerves, and muscles,
6
  need to be 
considered before ILP is recommended. 
Recurrence or in-transit metastasis 
confined to a limb is reported to occur in 
5%–8% of melanoma patients. 
Satisfactory but much simpler treatment 
options than ILP are often available for 
this small group of patients. In some 
cases, simple surgical excision of one or 
two small in-transit metastases will be all 
that is required. If disease is more 
extensive but superficial, techniques 
such as cryotherapy, diathermy 
curettage, laser treatment, 
radiofrequency ablation, or direct 
cytotoxic drug injection into tumor 
nodules can be effective. For larger and 
more deeply placed lesions, local 
radiotherapy can be used. Recent studies 
have demonstrated that electroporation 
therapy, in which an electric field is 
applied across a tumor nodule via a 
circular array of needle electrodes after 
injection of a cytotoxic agent into it, is 
also effective in many cases. Thus, in 
patients who have limb recurrences of 
melanoma which are small and few in 
numbers, easily removed by surgical 
excision, or able to be treated by one of 
the other simple methods outlined above, 
it is difficult to justify treatment by ILP. 
In some (but not all) patients, further 
local or in-transit recurrences will 
become apparent later, but often these 
are able to be dealt with by simple means 
once more. There remains, however, a 
group of patients with disease that is too 
advanced or too widespread within the 
limb to be able to be treated by these 
methods, and it is in this situation that 
isolated regional chemotherapy using a 
technique such as ILP is indicated. 
Acknowledging the effectiveness of ILP, 
but recognizing the limitations and risks 
imposed by its technical complexity, 
simpler and safer regional chemotherapy 
techniques have been sought. Direct 
intra-arterial infusion of cytotoxic agents 
was simple, but although an enhanced 
first-pass effect of the drugs on the tumor 
was achieved, CR rates were 
unimpressive and systemic drug toxicity 
was a major problem. Another 
alternative technique was described as 
tourniquet infusion but, again, response 
rates were low and systemic drug effects 
were inevitable because only very brief 
occlusion of venous outflow from the 
limb was achieved.
7
 
At the Sydney Melanoma Unit, we 
introduced in 1992 an alternative 
technique that we called isolated limb 
infusion (ILI). This has produced results 
generally comparable to those achieved _________________________________________________________________________________ 
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by ILP, but without requiring complex 
equipment, many staff, and long periods 
of operating time. We have found the 
technique to be well tolerated, even by 
frail and elderly patients, allowing 
effective palliative treatment to be given 
to individuals who would not be 
considered fit for treatment by 
conventional ILP. Details of the ILI 
procedure have been reported 
elsewhere,
8
 but it is, in essence, a very 
low flow ILP performed without 
oxygenation via standard radiological 
catheters (6–8 FG). These are inserted 
percutaneously in the radiology 
department prior to the actual ILI 
procedure in the operating room, which 
involves only 20–30 minutes of drug 
exposure. Systemic drug leakage is 
minimized by routine use of a pneumatic 
tourniquet and a generous washout of the 
limb vasculature prior to deflation of the 
tourniquet and removal of the catheters. 
These maneuvers virtually eliminate the 
risk of systemic side effects, with 
systemic melphalan leakage rarely 
exceeding 1%–2% (calculated from 
measurements of systemic melphalan 
concentrations by high performance 
liquid chromatography). The results of 
ILI for melanoma in terms of OR and CR 
rates have been similar to those achieved 
by conventional ILP, and it has been 
found easily possible to repeat the 
procedure if a satisfactory response is not 
achieved after an initial ILI or if 
recurrence in the limb occurs later. 
Although the effectiveness of isolation 
techniques used during conventional ILP 
have improved over the years, as the 
article by Daryanani et al.4 reports, and a 
decrease in systemic drug leakage and 
associated systemic complications has 
been achieved as a result of this, the 
procedure remains complex and costly 
and can produce considerable regional 
morbidity. Because ILP has no effect on 
survival, its objective must be to achieve 
local disease control in a limb. However, 
it should only be used if it is likely to 
produce better or more long lasting 
results than other forms of locoregional 
treatment that are simpler, cheaper, less 
invasive, and safer. 
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  Introduction 
 
Melanoma is often diagnosed in young adults and a significant number of these 
patients are women in their reproductive phase of life. The real incidence of 
melanoma during pregnancy is unknown. Smith and Randall reported in 1969 an 
incidence of 2.8 per 1,000 deliveries.1 The influence of pregnancy on the prognosis 
of melanoma has been a controversy ever since 1951 when Pack and Scharnagel 
reported ten pregnant patients with malignant melanomas of which five died 
within 30 months after diagnosis.2 Since then numerous case reports have also been 
presented showing a worse prognosis compared to non-pregnant women and the 
dilemmas in treatment policies.3,4 But in 1985 the World Health Organization 
melanoma program initiated a retrospective study of melanoma in relation to 
pregnancy which showed that there were no survival differences between 
pregnant and non-pregnant Stage I patients after correction for tumor thickness.5 
Thus the literature is confusing, and reports on the behavior of the melanoma are 
contradictory.  
It has been hypothesized that the frequency and prognosis of melanomas in 
women is influenced by hormonal or reproductive factors. However previous 
studies have failed to prove that the presence of hormonal receptors in human 
melanoma cells carries a poorer prognosis of the disease.6-8 Traditional quantitative 
analyses suggest that a proportion of the melanoma cells carry a type II oestrogen 
receptor, but the absence or presence of this receptor does not appear to affect the 
individual outcome of the patient.8 This has been underlined in recent reports in 
which the relation between the use of oral contraceptives and the prognosis could 
also not be proven.9-11  
The purpose of this present study is to report our single institution’s experience 
with melanoma arising during pregnancy. Specific goals of the study are to 
determine the disease free survival (DFS) and overall survival (OS) rates of this 
group of patients during a long term follow up period. Furthermore, the impact of 
Breslow thickness, ulceration, vascular invasion, histologic subtype and location of 
the tumor on the DFS and overall survival was studied.  
 ________________________________________                    C h a p t e r  V 
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  Patients and Methods 
 
Between 1965 and 2001, a total of 2567 patients were diagnosed and treated for a 
cutaneous malignant melanoma at the University Medical Center Groningen. The 
population consisted of 991 male patients (39%) and 1576 female patients (61%). 
For the purposes of this study, 46 female melanoma patients with a median age of 
30 (range 18-46) years were identified to be pregnant and diagnosed with an 
American Joint Committee on Cancer (AJCC) TNM Stage I/II melanoma (Table 1)12. 
This pregnant group was compared to a non-pregnant control group. This age-sex 
control population was selected of those Stage I/II cutaneous female melanoma 
patients between 16 and 46 years of age who were not pregnant at time of 
diagnosis. This subgroup consisted out of 368 female non-pregnant Stage I/II 
melanoma patients with a median age of 36 (range 17-45) years. The clinical data 
retrieved from the Groningen melanoma database included age at diagnosis, site of 
the primary tumor, and stage at diagnosis. All histological slides were reviewed at 
our institution. The histopathological characteristics recorded included the 
histologic subtype of melanoma (superficial spreading, nodular or unknown), 
tumor ulceration, Breslow’s depth of invasion (in millimeters) and the presence or 
absence of vascular invasion.  
 
Treatment 
All patients were treated according to the guidelines of the Dutch Melanoma 
Working Party.13 Most patients who were referred to our institution underwent a 
diagnostic excision of their primary lesions elsewhere. The patients were referred 
for further treatment consisting mostly of wide excision only. The sentinel lymph 
node biopsy was performed since 1995 in 6 patients, all of which were postpartum. 
Fifteen (33%) patients in the pregnant group (all postpartum) received an adjuvant 
hyperthermic isolated limb perfusion with melphalan compared to 144 patients 
(39%) in the non-pregnant group. The adjuvant limb perfusion was in the past part 
of an institutional protocol or part of the EORTC study on adjuvant limb perfusion 
in Stage I melanoma. _____________________________________________________________ 
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Staging T  classification† 
 
Thickness* 
 
Ulceration Status 
 
1A 
T1A  ≤ 1.0 mm  w/o ulceration 
 
T1B  ≤ 1.0 mm  with ulceration   
1B 
T2A  1.01 – 2.0 mm  w/o ulceration 
 
T2B  1.01 – 2.0 mm  with ulceration   
2A 
T3A  2.01 – 4.0 mm  w/o ulceration 
 
T3B  2.01 – 4.0 mm  with ulceration   
2B 
T4A  >4.0 mm  w/o ulceration 
 
2C  T4B  >4.0 mm  with ulceration 
†2002 AJCC TNM classification; * Thickness according to Breslow  
 mm: millimeter; w/o: without  
 
Table 1. 2002 AJCC TNM melanoma staging system12 
 
Follow up   
All patients were regularly followed in the outpatient clinic for regional and/or 
distant failures. The follow up scheme did not include lab controls, only yearly 
chest x-rays. Regional failure was defined by the histological or cytological 
confirmation of tumor cells at the site of the primary tumor and/or along its 
lymphatic drainage pathway to the first lymph node basin. Distant failure was 
defined by radiological detection of suspected lesions by means of computer 
tomography (lungs, brain), ultrasound (liver) and bone scintigraphy. Histological 
confirmation of distant failure was not obtained in all cases. Appropriate treatment 
of recurrences was performed depending of the type and site of recurrence. No 
patient received any kind of adjuvant systemic treatment.  ________________________________________                    C h a p t e r  V 
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Statistics 
The software package SPSS 10.0 for Windows (SPSS, Inc., Chicago, IL) was used for 
statistical analysis. To compare the two groups in Breslow thickness the Mann 
Whitney U test was used. Disease free survival was defined as the time between 
the date of diagnosis and the date of first recurrence. The follow up time was 
defined as the time between the date of diagnosis and the date of disease-specific 
death or last visit to the outpatient clinic. The Kaplan-Meier, Cox regression and 
logistic regression analysis tests were performed in order to identify the risk 
factors and to calculate the 10-year DFS and 10-year overall survival curves with 
the date of diagnosis, first recurrence or death acting as end-points. To compare the 
survival distributions between the pregnant and the non-pregnant group a log 
rank test was used. Potential prognostic factors were calculated using a univariate 
and multivariate analysis. A p-value less than 0.05 was considered to be significant. 
 
  Results 
 
Clinical data 
Data on 610 consecutive women of childbearing age with cutaneous melanomas 
were analyzed. Fifty seven patients were pregnant at the time of diagnosis (46 
Stage I/II, 8 Stage III and 3 Stage IV). The number of Stage III and IV patients was 
not sufficient for statistical analysis and therefore not considered. The age-sex non-
pregnant control group consisted of 368 of the total 610 childbearing female 
patients who had sufficient clinical and pathologic available. The clinical variables 
of the Stage I/II pregnant patients and the non-pregnant patients are presented in 
Table 2. The median follow up time was similar for both the pregnant and non-
pregnant groups. The median follow up time for the pregnant patients was 106 
(range 3–260) months and 109 (range 1–356) months for the non-pregnant patients. 
Extremity primary melanomas predominated in this group of patients. For the 
pregnant group, 36 patients (78%) had extremity melanomas with 28 patients 
originating from the lower extremities (61%). Seven patients had trunk (thorax, 
abdomen and back) melanomas (15%) and 3 patients had head and neck 
melanomas (7%). For the non-pregnant group the percentages were respectively  _____________________________________________________________ 
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Logistic 
regression 
Total Group  Pregnant group 
 
N           % 
 
Non-pregnant group 
 
N           % 
 
 
DFS 
 
OS 
Patients (N = 414) 
 
46 11  368  89     
Median Age 
(range) 
30 (18–46) yrs  36 (17 – 45) yrs  ns ns 
Upper extremity  8  17  51  14 
Lower extremity  28  61  229  62 
p<0.004  ns 
Trunk 7  15  66  18  ns ns 
Head and Neck  3  7  22  6  ns ns 
ns = not statistically significant; DFS = Disease free survival; OS = Overall survival 
 
Table 2. Demographic data of the pregnant and non-pregnant group and logistic 
regression analysis on DFS and OS 
 
76%, 18% and 6%. See Table 2 for a summary of the primary tumor locations. 
Patients were staged according to the 2002 AJCC TNM system as presented in 
Table 3.   
 
Histopathological Data 
All primary tumors were histologically classified according to histologic subtype, 
Breslow thickness, vascular invasion and tumor ulceration and are summarized in 
Table 4. There was no significant difference between the two groups in histologic 
subtype. The majority of the tumors were superficial spreading melanomas, 43% in 
the pregnant group compared to 48% in the non-pregnant group. There was also 
no difference in the frequency of the nodular type melanoma (20% pregnant vs. 
13% non-pregnant, ns). In the pregnant group the median Breslow thickness was 
2.0 mm compared to 1.7 mm in the non-pregnant group (ns, p=0.119 Mann ________________________________________                    C h a p t e r  V 
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Whitney U test). In the pregnant group the incidence of blood vessel invasion was 
9% compared to 2% in the non-pregnant group (ns, p>0.05). The number of tumors 
that were classified as ulcerating was also comparable in both groups.  
 
Disease free and Overall Survival  
For the Stage I melanomas the 10-year DFS was calculated to be 88% for the 
pregnant group compared to 86% for the non-pregnant patients (p=0.6541). The 10-
year OS was respectively 94% and 90% (p=0.6977). Patients who had Stage II 
disease and were pregnant had a 10-year DFS of 67% compared to 73% for the 
Stage II non-pregnant patients (p=0.7322). The OS for the Stage II patients was 
respectively 82% and 81% (p=0.7162) (see Fig. 1 and 2). Logistic regression analysis 
showed that increasing Breslow thickness (p<0.005) and the presence of ulceration 
(p<0.036) significantly led to a higher mortality. No significant effect of vascular 
invasion, tumor type, tumor location or pregnancy could be detected on the overall 
survival. Logistic regression analysis with DFS as dependent variable revealed that 
the length of the DFS is related to increasing Breslow thickness (p<0.006), 
ulceration (p< 0.010), location of the tumor (extremity melanoma) (p<0.004), 
histologic subtype (nodular melanoma) (p<0.002) but not vascular invasion (ns, 
p=0.076) (Table 2 and 4).  
 
 
Staging* Pregnant 
N           % 
Non-pregnant 
N           % 
1A 11  24  113  31 
1B  13 28 96 26 
2A  13 28 94 26 
2B  5  11 45 12 
2C  4  9 20 5 
* See Table 1 
 
Table 3 Staging of the pregnant and non-pregnant patients according to the 2002 TNM 
AJCC system12 _____________________________________________________________ 
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 In this model 30% of the variance of the DFS could be explained by the model. 
Although pregnancy showed no significant effect on the DFS, it did reveal a trend 
towards a longer DFS in the non-pregnant patients. 
 
  Discussion 
 
The possible influence of hormonal factors on the pathogenesis and biologic 
behavior of melanoma have intrigued scientists and clinicians on the basis of 
clinical or anecdotal reports suggesting a detrimental influence of concurrent 
pregnancy. The earlier hypothesis was that during pregnancy there was an 
increase in melanin stimulating hormone (MSH), oestrogen and progesterone 
which in turn lead to increased pigmentation and size of benign naevi and even 
possible malignant transformation.14 But recent reports have denied the expression 
of estrogen receptors on human melanoma cells that affect the outcome of the 
disease.7,15 In a large cohort study of sub-fertile women, Venn et al. reported no 
evidence of an increase in melanoma risk in women who received exogenous 
hormones for in vitro fertilization, compared to a control group.16 Thus there are to 
date no clear indications that exogenous hormone stimulation or hormonal 
changes during pregnancy stimulate the growth of the primary tumor or of 
potential micro-metastases. Furthermore, there is also no evidence that exogenous 
hormones, such as oral contraceptive medication, are contraindicated after 
treatment for a melanoma. 
 
In our research the effect of pregnancy on melanoma progression was determined 
by comparing the 10-year DFS and overall survival in female patients of 
childbearing age, pregnant vs. non-pregnant, at the time of diagnosis of clinically 
localized melanoma. Our study shows no difference in the 10-year DFS between 
the pregnant group and the non-pregnant group (Stage I 88% vs. 86%, Stage II 67% 
vs. 73%) and no significant difference in the 10-year overall survival (Stage I 94% 
vs. 90%, Stage II 82% vs. 81%) (Figs.1 and 2). Several large international studies 
including the report from the World Health Organization have attempted to 
answer this same question about a decade ago using multivariate regression 
analyses.5,17-21 
 ________________________________________                    C h a p t e r  V 
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Logistic regression    Pregnant group
 
N           % 
Non-pregnant group
 
N           %  DFS OS 
Histologic subtype 
 
 
 
Unknown / other  17  37  145  39 
SSM 20  43  177  48 
Nodular  9 20  46  13 
p<0.002  ns 
Breslow thickness 
(mm)* 
      
0 – 0.75  12  26  116  32 
0.76 – 1.50  14  30  122  33 
1.51 – 4.0  14  30  97  26 
> 4.0  6  13  33  9 
p<0.006  p<0.005 
Vascular invasion        
Absent 39  85  328  89 
lymphatic 2  4  15  4 
Blood vessel  4  9  8  2 
Unknown 1  2  17  5 
ns  
(p=0.076) 
ns 
Ulceration        
Yes 10  22  84  23 
No 36  78  284  77 
p<0.010  p<0.036 
SSM = Superficial Spreading Melanoma; * sum of percentages may not add up to 100% 
due to rounding; DFS = Disease free survival, OS = Overall survival, ns = not statistically 
significant  
Table 4 Histopathological data of the primary tumor and logistic regression analysis on 
DFS and OS _____________________________________________________________ 
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 Fig 1. Disease free survival pregnant vs. non pregnant for Stage I and Stage II AJCC 
 
Data from these studies suggest that pregnant women with the previous AJCC 
staging system Stage I and II melanoma (primary site only, with any tumor 
thickness) did not show any survival or DFS difference if treated promptly and 
appropriately. However the majority of these studies fail to mention the length of 
the follow up period. Two similar reports published by Duke University showed a 
significant shorter DFS in the pregnant group without any effect detrimental on 
overall survival.22,23 They reported that 51% of the pregnant patients and 68% of 
control patients remained disease free at 10 years. But although pregnancy showed 
no significant effect on the DFS in this series, it did possibly reveal a longer DFS in 
the non-pregnant patient. 
  94 ________________________________________                    C h a p t e r  V 
Overall survival pregnant vs non-pregnant
60%
70%
80%
90%
100%
0 20 40 60 80 100 120 140
time in months
p
e
r
c
e
n
t
a
g
e Pregnant Stage I
Non pregnant Stage I
Pregnant Stage II
Non Pregnant Stage II
p=0.6977
p=0.7162
Fig 2. Overall survival pregnant vs. non-pregnant for Stage I and Stage II AJCC 
 
An interesting phenomenon is the slightly increased median thickness of the 
primary melanomas in the pregnant patients compared to the non-pregnant group 
in this study and other studies.5,19,23 In this series we noted thicker primary tumors 
(median 2.0 vs. 1.7 mm, p=0.119) in the pregnant patients, but we failed to show a 
significant effect on the DFS or OS. Overall the general thought that naevi enlarge 
or that new naevi arise during pregnancy. The hypothesis is that salient signs of 
early melanoma, growth and change, may be initially misinterpreted as 
physiologic pregnancy-related changes leading to a change in diagnosis.24 
However Pennoyer et al. recently reported that only a small proportion of naevi 
(6%) showed a change during pregnancy.25 Further research is necessary to confirm 
these results in a larger study population. If this is confirmed, this would mean 
that the advice to pregnant women should be the same as to non pregnant women 
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that timely biopsy of all suspicious naevi should be performed and not deferred to 
after delivery.24 
 
Our study also focused on the effect of Breslow thickness, ulceration, vascular 
invasion, histologic subtype and location of the tumor on the DFS and overall 
survival in the pregnant patient and in the non-pregnant group. In both the 
pregnant and in the non-pregnant group there was no difference in the presence of 
ulceration, vascular invasion or location of the primary tumor. Primary tumor 
locations were comparable with the literature where extremity melanomas 
predominate in this group of patients.26 Logistic regression analysis on mortality 
and DFS showed that increasing Breslow thickness (OS: p<0.005, DFS: p<0.006) and 
the presence of ulceration (OS: p<0.036, DFS: p<0.010) were identified as 
independent prognostic factors. This was previously reported in the literature and 
is the foundation on which the 2002 AJCC TNM classification is based.12 
Furthermore logistic regression analysis on DFS also showed that extremity 
melanoma (p<0.004) and nodular type melanoma (p<0.002) are prognostic 
unfavorable factors of Stage I/II melanoma. Although we could not confirm 
vascular invasion as being a prognostic factor, we did establish a trend towards a 
poorer prognosis (p=0.076).  
   
In conclusion, based on these results and a critical review of the literature, 
pregnancy at the time of diagnosis of clinically localized invasive melanoma is not 
a risk factor for disease progression. Pregnant patients may present with thicker 
melanomas and pregnancy may decrease disease free survival but neither 
melanoma thickness nor disease free survival were significantly different between 
pregnant and non-pregnant patients in this study. In melanoma patients pregnant 
at the time of diagnosis, survival is still dependent on the tumor thickness and the 
absence or presence of ulceration. Patients should therefore be counseled regarding 
these factors and not the pregnancy.  ________________________________________                    C h a p t e r  V 
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The number of pregnant women who are newly 
diagnosed with malignant disease annually in the U.S. 
is approximately 1 per 1000 population.
1 Melanoma, 
breast carcinoma, cervical carcinoma, leukemia, and 
lymphoma are the most common types of malignant 
disease that arise during pregnancy.
2,3 The incidence 
of melanoma is rising at a rapid rate, and it is 
projected that 1 in 68 Americans born in the year 
2002 will develop an invasive melanoma during their 
lifetime. Melanoma is the sixth most common 
malignancy in women. It is the most common 
malignancy in women ages 25–29 years, and it is 
associated with a younger age at the time of 
presentation.
4 These trends suggest that approximately 
35% of women with melanoma are of   
© 2003 American Cancer Society 
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childbearing age.
2,5 In this issue of 
Cancer, Daryanani et al. provide further 
evidence that pregnancy does not have 
an adverse effect on prognosis in patients 
with melanoma.6 The information from 
this single-institution study is valuable; 
however, the management of patients 
with melanoma with respect to 
pregnancy and hormonal contraception 
remains a challenge. The purpose of this 
editorial is to discuss the management of 
these patients and to enhance the 
information provided by Daryanani et 
al.
6 It is clear that we will encounter 
increasing numbers of women of 
childbearing age who may be pregnant at 
the time of diagnosis of melanoma, who 
may desire to become pregnant after the 
diagnosis, or who may desire to use oral 
contraceptive pills to prevent pregnancy 
after a diagnosis of melanoma. In clinical 
practice, how these scenarios are 
approached may vary from institution to 
institution and from physician to 
physician. This is simply a reflection of 
the historic controversy that has 
surrounded the effect of pregnancy and 
hormones on melanoma and the 
appropriate management of melanoma in 
pregnant women and in women of 
childbearing age. Although no rigorous, 
randomized, prospective trials exist to 
answer all of these questions definitively, 
a wealth of epidemiologic data and 
controlled clinical studies provides 
consistent insight into optimal 
management approaches.  
 
Pregnancy at the Time of Diagnosis 
Numerous well controlled studies, such 
as that by Daryanani et al., have 
provided strong evidence that the clinical 
course, prognosis, and overall survival of 
pregnant women with melanoma 
(American Joint Committee on Cancer 
[AJCC] Stage I–II) is similar to that in 
nonpregnant women.
2,3,5–9 The prognosis 
of pregnant women with melanoma still 
is dependent primarily on tumor 
thickness and ulceration status.
10  Some 
studies have shown that thicker lesions 
are associated with pregnancy, 
presumably as a result of delayed 
diagnosis.
8 Early detection is critical, and 
prompt biopsy of suspicious lesions is 
important and should not be deferred 
until after pregnancy. The earliest sign of 
a melanoma is a change in the size, 
shape, or color of a lesion. The earliest 
symptom is persistent itching of a 
lesion.
11  Biopsies and wide local 
excisions can be performed safely during 
pregnancy. Minor variations in logistics 
and techniques easily can accommodate 
the recommendations of the patient’s 
obstetrician. For example, some of our 
obstetricians recommend recording fetal 
heart rate before and after the mother 
undergoes a wide local excision. 
 
Can Pregnant Patients Undergo 
Sentinel Lymph Node Biopsy Safely? 
Sentinel lymph node (SLN) mapping and 
biopsy represent one of the most 
significant advances in the management 
of patients with melanoma during the 
past decade. The most powerful 
prognostic factor related to recurrence 
and survival in patients with clinically 
localized melanoma is the status of the 
SLN.
12  We offer SLN biopsy at our 
institution to relatively healthy, 
nonpregnant patients with melanomas 
measuring ≥ 1.0 mm or < 1.0 mm with 
other adverse factors. This technique 
uses preoperative intradermal injection 
of 99mTc-sulfur colloid (1–3 millicuries 
[mCi]; CIS-US, Inc., Bedford, MA) and 
intraoperative, intradermal injection of 
isosulfan blue dye (Lymphazurin 1%; 
Hirsch Industries, Inc., Richmond, VA) 
around the intact tumor or biopsy site. 
Lymphatic mapping and SLN biopsy are 
performed with the aid of a hand-held 
gamma counter and visualization of blue 
lymph nodes. Fetal doses < 100 milli-_____________________________________________________________ 
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grays (mGy) of radiation do not increase 
the incidence of fetal malformation. The 
Society of Nuclear Medicine 
recommends a pregnancy test in patients 
prior to any procedure that would expose 
a fetus to > 50 mGy. The dosages and 
radiopharmaceuticals used for lymphatic 
mapping deliver whole fetal doses of < 5 
mGy. Therefore, these radiopharma-
ceuticals at dosages used for lymphatic 
mapping are not contraindicated in 
pregnant patients and carry negligible 
risk.
13–15 The safety of isosulfan blue dye 
in pregnancy poses additional questions. 
The rate of allergic reactions to the dye 
reportedly is as high as 2%, and the 
incidence of life-threatening anaphy-
lactic reaction requiring vigorous 
resuscitation is reported at 0.7–1.1%.
16,17 
Due to the risk of this rare but potentially 
catastrophic event of anaphylaxis in 
pregnant patients, we now use 
radiocolloid alone for SLN biopsy in 
pregnant patients at our institution. 
Alternatively, in women who are in 
middle to late pregnancy and who have 
undergone narrow excision of their 
primary melanoma with clear histologic 
margins, definitive wide local excision 
and SLN biopsy with radiocolloid and 
blue dye may be delayed until after 
delivery, with close clinical follow-up 
for the duration of the pregnancy. 
 
Implications for the Fetus 
What about the risk of metastasis to the 
placenta and fetus? Fortunately, 
placental and fetal metastasis from 
maternal malignant disease is an 
exceptionally rare event.
18 However, 
melanoma is the most common type of 
malignancy to metastasize to the 
placenta and fetus, representing 30% of 
placental metastases and 58% of fetal 
metastases. Approximately 19 patients 
with melanoma placental metastasis have 
been reported, with maternal death in all 
patients: 80% within 3 months of 
delivery. Five patients with fetal 
metastasis have been reported, with four 
resulting in death. Therefore, although 
these occurrences are exceedingly rare, 
pregnant patients with melanoma at our 
institution are counseled, the placenta is 
sent for histologic evaluation, and the 
neonatal service is notified. 
 
Pregnancy After Diagnosis 
Although there is no clear evidence to 
suggest that prior, present, or subsequent 
pregnancy adversely affects the 
prognosis of patients with melanoma, 
there are no standard, defined guidelines 
for patients who desire to become 
pregnant after diagnosis and treatment of 
melanoma. Recommendations regarding 
the length of time to wait after a 
diagnosis vary from physician to 
physician, and some physicians 
recommend against getting pregnant. 
Significant proportions of patients with 
localized disease (AJCC Stage I–II) 
harbor occult disease and eventually 
develop recurrences. It is not completely 
predictable who will and who will not 
develop recurrent disease. Many survival 
models demonstrate that tumor thickness 
is the single most important predictor of 
a probability of cure in patients who do 
not undergo SLN biopsy. Although 
approximately 50% of recurrences 
develop by 3 years in patients with thick 
lesions, late recurrences occur in some 
patients, even with thin lesions, longer 
than a decade after treatment.
19 If 
recurrence develops during pregnancy, 
then it may be disastrous both medically 
and emotionally, potentially altering 
treatment options and with a risk of 
placental and fetal metastasis, although 
these are rare. The use of chemotherapy, 
radiation therapy, radiodiagnostic tests, 
and general anesthesia for extensive 
surgical procedures may have harmful 
effects on the fetus/ newborn. Our 
recommendation about how long to wait ________________________________________                       E d i t o r i a l 
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before becoming pregnant after a 
diagnosis of melanoma is on a case-by-
case basis, depending primarily on the 
risk of recurrence (tumor thickness and 
tumor stage), age of the patient, and 
desire to become pregnant. There is no 
exact answer, and our approach is to 
educate patients completely about the 
risks to help them make informed 
decisions. At our institution, patients 
typically wait 0–5 years, depending on 
the aforementioned factors. For example, 
a woman age 40 years with a melanoma 
measuring 0.3 mm in thickness has only 
an approximate 1–3% risk of recurrence 
within 5 years, and we would not 
necessarily advise her to wait if she 
desires to become pregnant and finds this 
an acceptable risk. Alternatively, a 
woman age 21 years with a melanoma 
measuring 4.0 mm thick generally would 
be advised to wait for 3–5 years. Each 
patient is approached individually, with 
the patient ultimately making her own 
informed decision. If the patient does 
become pregnant, then self-examination 
of the skin and lymph nodes on a 
monthly basis is stressed. Although 
controlled studies consistently demon-
strate no statistically significant 
difference in survival for melanoma in 
pregnant patients compared with non-
pregnant patients, the tragedy of a child 
losing their mother soon after birth is 
highlighted by clinical examples and 
case reports. Merkus et al. illustrated this 
point in their description of a couple who 
consulted the gynecologist repeatedly 
because of a primary fertility disorder.
20 
A few days after the woman started the 
hormonal treatment that preceded the in 
vitro fertilization procedure, she noted 
swelling in the right groin area for which 
she consulted a surgeon. It was found 
that the swelling was a metastasis from a 
primary cutaneous melanoma that had 
been excised from her leg 6 months 
previously. Her first in vitro fertilization 
treatment resulted in a pregnancy, which 
ended with the birth of a healthy boy. 
However, the placenta showed 
melanoma metastases, and the mother 
died 2 months after the birth of her son. 
Although recurrence and survival may 
not have been affected directly by 
pregnancy or hormonal treatment, the 
tragedy of this situation is readily 
apparent. 
 
The Desire Not to Become Pregnant 
(Oral contraceptives) 
Given the concerns that may face a 
woman of childbearing age who has been 
diagnosed with melanoma, what about 
oral contraceptive use? Many studies 
with thousands of patients have 
demonstrated no significant increased 
risk for the development of melanoma 
associated with oral contraceptive use, 
including duration of use, age started, 
years since first or last use, or current 
use.
21 There also is no evidence showing 
that hormone replacement therapy for 
menopause plays an etiologic role in the 
development or recurrence of melanoma. 
Because a very small risk of 
contraceptive or replacement hormones 
on recurrence has not been excluded in a 
prospective trial, some patients and/or 
physicians may choose not to accept 
even a theoretical risk and, instead, 
choose nonhormonal contraception or 
menopause symptom relief.  
 
Conclusions 
From previous studies, including that 
reported by Daryanani et al. in this issue 
of  Cancer,
6 we may conclude that 
pregnancy or hormone use before, 
during, or after a woman is diagnosed 
with melanoma does not appear to 
influence survival, which provides 
important information that should 
simplify the clinical management of 
these patients. However, generalized _____________________________________________________________ 
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guidelines may not be applicable or 
appropriate because of patient 
variability. In clinical practice, this 
translates into individualized patient 
management. The patient with melanoma 
who is diagnosed during pregnancy is 
managed best by early and continual 
involvement of a multidisciplinary team 
with clinical and psychosocial expertise 
in melanoma therapy. 
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  Introduction 
 
The worldwide incidence of melanoma is increasing and despite significant 
advances in prevention, early detection and treatment, the mortality rate continues 
to increase.1-3 Melanoma before puberty is rare, but the incidence increases steadily 
thereafter in each decade. The steepest trends of increasing incidence are in those 
aged over 65 and the lowest trends are in the younger age groups. Approximately 
1 to 4% of all new melanoma cases occur in patients under the age of 20 years and 
only 0.3% among those younger than 14 years.4-6 The highest rate is reported from 
Australia where 0.3% to 0.9% of the patients are under the age of 15.7 Spitz nevus, 
also known as juvenile melanoma or spindle and epithelioid nevus, is a benign 
tumor that predominantly affects children and adolescents.8 Due to its histological 
overlap with cutaneous melanoma, misdiagnoses of Spitz nevi as well as 
cutaneous melanoma is not uncommon. The diagnosis of melanoma is sometimes 
even delayed until the patient develops recurrent disease or distant metastases. It 
is known that genetic susceptibility and chronic exposure to sunlight during 
childhood are risk factors for developing a melanoma.7,9 Factors such as the 
presence of a giant congenital melanocytic nevi, the phenotype of the nevus, 
xeroderma pigmentosum and dysplastic naevus syndrome are all associated with a 
greater risk for developing a melanoma. In this study we analyzed the childhood 
and juvenile melanomas treated at our institution with a special focus on 
differences in clinical characteristics, prognostic factors, disease free and overall 
survival in comparison with those of adults. 
 
  Patients and Methods 
 
Between 1965 and 2003, a total of 2567 patients were diagnosed and treated for a 
cutaneous melanoma at the Groningen University Medical Center (GUMC). The 
population consisted of 991 male patients (39%) and 1576 female patients (61%). 
During this period, 55 patients (2.1%) of which 29 males (53%) and 26 females 
(47%), were under the age of 19 years old. Of these 55 patients, six were under the 
age of twelve (10.9%), and 49 were between 12 and 19 years old (89.1%). Because of 
the low number of patients under the age of 12 years, they were not considered in ________________________________________                  C h a p t e r  V I 
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the analysis of the prognostic factors. The melanomas were staged according to the 
2002 American Joint Committee on Cancer (AJCC) staging system.10 The clinical 
and histopathological data was retrieved from the Groningen melanoma database 
(Table 1 and 2). The clinical data retrieved included gender, age at diagnosis, 
location of the primary tumor, and stage at diagnosis. The histopathological 
characteristics recorded included the histologic subtype of melanoma (superficial 
spreading, nodular or other/unknown), type of cell (spindle, epithelioid or other) 
Breslow’s depth of invasion (in millimeters), tumor ulceration, the presence or 
absence of vascular and/or lymphatic invasion and mitotic rate per 5 high power 
fields (per mm2). All histological slides were reviewed at our institution.  
 
Treatment 
All patients were treated according to the guidelines of the Dutch Melanoma 
Working Party.11 Most patients, who were referred to the GUMC, underwent 
excision of their primary lesions elsewhere. The patients were referred for further 
treatment consisting mostly of wide excision only. In certain high risk patients a 
so-called en-bloc (wide excision plus lymph node dissection) excision was 
performed. Therapeutic lymph node dissection was performed in patients staged 
with pathological involved nodes. A sentinel lymph node biopsy was performed 
since 1995 in 2 patients. Fifteen (5 children and 10 juvenile) patients were subjected  
to an adjuvant hyperthermic isolated limb perfusion between the years of 1973 and 
1984. The adjuvant limb perfusion was till 1988 part of an institutional protocol for 
which the results have previously been published.12   
 
Follow up   
All patients were regularly followed in the outpatient clinic for regional and/or 
distant failures. The follow up included history, physical examination and yearly 
chest x-rays. Regional failure was defined by the histological or cytological 
confirmation of tumor cells at the site of the primary tumor and/or along its 
lymphatic drainage pathway to the first lymph node basin. Distant failure was 
defined by radiological detection of suspected lesions by means of chest-X-ray, CT 
(lungs, brain), ultrasound (liver) and/or bone scintigraphy. Appropriate treatment  _____________________________________________________________ 
 
  Children Juvenile  Control  group 
Total Patients  6 49  972 
Age median (range)  7 (3 – 10) yrs  17 (12 – 19) yrs  49 (20 – 93) yrs 
Male/Female (%)  3(50%) / 3(50%)  26(53%) / 23(47%)  379(39%) / 593(61%) 
Extremity  2 (33%)  31 (63%)  594 (61%) 
Trunk  2 (33%)  14 (29%)  229 (24%) 
Head and neck  2 (33%)  4 (8%)  149 (15%) 
Stage 0 (in situ)  1 (17%)  3 (6%)  0 
Stage I  1-IA (17%)  11-IA (23%) 
5-IB (10%) 
214-IA (22%) 
200-IB (21%) 
Stage II  3-IIB (50%)  9-IIA (18%) 
3-IIB (6%) 
4-IIC (8%) 
177-IIA (18%) 
128-IIB (13%) 
54-IIC (5%) 
Stage III  1-IIIC (17%)  13-IIIB (27%)  25-IIIA (3%) 
110-IIIB (11%) 
50-IIIC (5%) 
Stage IV  0 1  (2%)  14  (1%) 
Table 1: Clinical data and staging10 
 
of recurrences was performed depending of the type and site of recurrence. No 
patient received any kind of adjuvant systemic treatment. 
 
Control group and statistics 
An adult control group was used to construct explanatory models for comparison 
between the two groups. Statistical methods used included logistic and linear 
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regression models (multivariate) in order to calculate the prognostic factors 
determining the disease free survival and overall survival for the adult control  
 
  Children Juvenile  Control  group 
0 – 1.0  2 (33%)  14 (29%)  236 (24%) 
1.01 – 2.0  0 (0%)  19 (39%)  268 (28%) 
2.01 – 4.0  2 (33%)  11 (22%)  301 (31%) 
> 4.0  2 (33%)  5 (10)  167 (17%) 
Breslow 
thickness 
(mm) 
Median(range)  3.9 (i.s. – 5.0)  1.6(i.s. – 8.0)  2.0 (0.2 – 35.0) 
Yes  2 (33%)  20 (41%)  280 (29%) 
Ulceration 
No  4 (67%)  29 (59%)  692 (71%) 
SSM  1 (16.7%)  16 (33%)  597 (61%) 
Nodular  1 (16.7%)  8 (16%)  278 (29%) 
CGN  1 (16.7%)  0 (0%)  0 (0%) 
Histogenic 
subtype 
Other  3 (50%)  25 (51%)  97 (10%) 
1 per 5 hpf  1 (16.7%)  7 (14%)  412 (42%) 
2-4 per 5 hpf  1 (16.7%)  9 (19%)  288 (30%) 
>5 per 5 hpf  2 (33%)  6 (12%)  272 (28%) 
Mitotic rate 
Unknown  2 (33%)  27 (55%)  0 (0%) 
Absent  4 (67%)  31 (63%)  896 (92%) 
Lymphatic  0 (0%)  1 (2%)  36 (4%) 
Blood vessel  0 (0%)  1 (2%)  16 (2%) 
Vascular 
invasion 
Unknown  2 (33%)  16 (33)%  24 (2%) 
spindle  0 (0%)  4 (8%)  139 (14%) 
epithelioid  2 (33%)  15 (31%)  787 (81%) 
Type of cell 
Unknown 
/other 
4 (67%)  30 (61%)  46 (5%) 
mm: millimeter, SSM: superficial spreading melanoma, hpf: high power field CGN: 
Congenital giant naevus, i.s.: in situ 
 
Table 2: Histopathological data 
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group. These models were then directly applied to the juvenile group in order to 
asses the impact and the weight of the explanatory variables on the subsequent 
dependent variables between both groups. To compare the two groups in Breslow 
thickness the Mann Whitney U test was used. Disease free survival was defined as 
the time between the date of diagnosis and the date of first recurrence. The follow 
up time was defined as the time between the date of diagnosis and the date of 
disease-specific death or last visit to the outpatient clinic. The Kaplan-Meier and 
Cox regression analysis tests were performed in order to calculate the 10-year DFS 
and 10-year overall survival curves with the date of diagnosis, first recurrence or 
death acting as end-points. To compare the survival distributions between the 
juvenile and adult groups a log rank test was used. A p-value less than 0.05 was 
considered to be significant. The software package SPSS 10.0 for Windows (SPSS, 
Inc., Chicago, IL) was used for statistical analysis. 
 
  Results 
 
Clinical and Histopathological data 
Children (under 12 years old) 
Six children under the age of twelve years were identified to have a cutaneous 
melanoma (1 patient had an in situ melanoma, 1 Stage IA, 3 Stage IIB and 1 Stage 
IIIC). The median follow time was 65 (5 - 188) months. Of the six melanomas, two 
were located on the extremities (33.3%), two on the trunk (thorax and back, 33.3%) 
and two in the head and neck area (33.3%) (Table 1). The median Breslow thickness 
was 3.9 (range in situ – 5.0) mm (Table 2). None of the children were identified to 
have a dysplastic naevus syndrome or xeroderma pigmentosum. Of the six 
patients three developed local failure (50%) within 33 months after diagnosis 
(median time 9 (range 2-33) months). One patient developed distant metastases 
(16.7%). This patient had a congenital giant naevus that turned into a melanoma 
with a tumor thickness of 5.0 mm. This patient developed distant cutaneous and 
liver metastases within 3 months of diagnosis and died 2 months later. Of the other 
five patients, 2 are alive with disease (9 and 34 months) and three are disease free ________________________________________                  C h a p t e r  V I 
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(95, 130, and 188 months). The number of patients under the age of twelve was not 
sufficient for statistical analysis and therefore not considered.   
 
Juvenile (between 12 – 19 years old) 
Forty nine patients between the ages of 12 and 19 years old with a median age of 17 
(range 12 – 19) years were identified to have a cutaneous melanoma (3 in situ, 11-
IA, 5–IB, 9–IIA, 3–IIB, 4–IIC, 13–IIIB, and 1–IV). There were 26 males (53%) and 23 
females (47%) (p=ns compared to the adult group, Mann Whitney U). The median 
follow up time was 92 (4 - 366) months. Compared to the adult control group, there 
were significantly more patients who presented with a locally advanced stage IIIB 
(26.5%) in the juvenile group than in the adult group (11.3%) (p<0.01, chi square 
test). One patient was previously diagnosed with an acute lymphatic leukemia 
which was treated successfully with chemotherapy. Two patients were diagnosed 
by the dermatologists with having a dysplastic naevus syndrome. No patients had 
xeroderma pigmentosum. In this group, 31 patients (63%) had extremity 
melanomas with 27 patients originating from the lower extremities (55%). Fourteen 
patients had trunk (thorax, abdomen and back) melanomas (29%) and 4 patients 
had head and neck melanomas (8%). There was no difference in tumor location 
between the juvenile and adult control group (p=0.538, chi square test).  In the 
juvenile group the median Breslow thickness was 1.6 mm compared to 2.0 mm in 
the adult control group (ns, p=0.075 Mann Whitney U test). All histopathological 
data are summarized in Table 2.  
 
Regression analyses for disease free survival and overall survival 
Logistic and linear regression models were developed using DFS and OS as 
dependent variables and Breslow thickness, 2002 AJCC staging, age, gender, tumor 
location, histogenic subtype, mitotic rate, ulceration and vascular invasion as the 
independent variables. The models were set up for the control group as an 
exploratory regression analyses, with Conditional Forward Stepwise inclusion 
(OS) and Conditional Backward exclusion (DFS) of explanatory variables. Table 3 
and 4 shows in condensed form the comparison of the model between the control 
and the juvenile group. In the DFS model, increasing Breslow thickness, increasing 
age, male gender, tumor location and the presence of ulceration were calculated to 
be significant predictors for disease free survival in the adult control group. None  _____________________________________________________________ 
  
95% Confidence 
Interval for expected 
ß 
Group Variable  ß  Standard 
error ß 
p-
value 
Expected 
ß 
Lower Upper 
AJCC 0.385  0.044  <0.001 1.469  1.346  1.603 
Age 0.016 0.007 0.023 1.016  1.002  1.030  Control 
Constant -4.48  0.440  <0.001  0.011     
AJCC 0.617  0.245  0.012  1.854  1.148  2.994 
Juvenile 
Constant -4.86  1.545  0.002  0.008     
Table 3: Logistic regression model for survival 
 
of these variables reappeared in the juvenile group as significant predictors for 
disease free survival.In the juvenile group, only the variable histogenic subtype 
showed more or less a significant explanatory power (p=0.056). The explained 
variance in both models did not differ; the adult control group model explained 
11% variance while the model for the juvenile group explained 8% of the variance 
(R-square). 
In the survival model, the explained variance in both control and juvenile models 
were very different. In the adult control group, 18% of variance was explained by 
age and AJCC stage. In the juvenile group, 34% of the variation was explained by 
the AJCC stage, and age was a non-significant contributor to the explanation of 
survival (Nagelkerke R-square).  
 
10-year disease free and overall survival  
There was no difference between the two groups regarding the time to develop 
local recurrence. For the Stage I/II melanomas the 10-year DFS was calculated to be 
64% for the juvenile patients compared to 71% for the adult patients (p=0.236). The 
10-year OS was respectively 79% and 83% (p=0.198). Juvenile patients with Stage III 
disease had a 10-year DFS of 45% compared to 40% for the Stage III adult patients 
(p=0.778). The OS for the Stage III patients was 50% for both groups (p=0.464) (Figs. 
1-3). 
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Group Variable  ß  Standard  error  ß  p-value 
Breslow -1.776  0.656  0.007 
Age -0.359  0.097  <0.001 
Gender 12.073 3.169 <0.001 
Location -8.156  2.097  <0.001 
Ulceration  7.519 3.804 0.048 
Control 
Constant 83.507 -14.079 <0.001 
Histogenic subtype  -8.276  4.220  0.056 
Juvenile 
93.977 13.360 <0.001  Constant 
Table 4: Linear regression model for disease free interval 
 
  Discussion 
 
Melanoma in childhood and during the adolescent years is rare. Approximately 1 
to 4% of all new melanoma cases occur in patients under the age of 20 years and  
only 0.3% among those younger than 14 years.4-6 Because of the low incidence, a 
correct diagnosis is difficult to make by the clinician. The degree of difficulty has 
increased since Sophie Spitz published her paper about melanomas in childhood in 
1948.8 Although there were large similarities in histological features, she noticed 
that many melanomas in children were rarely malignant in behavior compared to 
adults. Due to its benign clinical behavior the term Spitz naevus was introduced as 
a separate entity. Usually they are under 1 cm in diameter and may resemble 
verrucae or small hemangiomas. Melanomas in children tend to be larger and quite 
strikingly clinically. Histologically, Spitz naevi are characterized by large spindle 
or epitheloid cells with sharp cytoplasmic borders. Architectural features 
supporting the diagnosis of Spitz naevi include symmetry, associated epidermal 
hyperplasia, multinucleated giant cells, and a wedge shaped silhouette. In contrast, 
a lack of maturation, deep mitosis, marked nuclear pleiomorphism; 
hyperchromasia and an expansive architecture of the dermis are suggestive 
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features of melanoma.13,14 Misdiagnosis is common and some melanomas are 
diagnosed when the tumor has already metastasized. Therefore all histological 
slides of all resected suspicious naevi in childhood should be reviewed by an 
experienced pathologist to minimize the misdiagnoses.  
In our study of patients with childhood and juvenile melanoma, 29 patients were 
male and 26 were female. This slight male preponderance in sex distribution is not 
in accordance with the literature where a female preponderance has been 
reported.15 This difference was however not significant. Compared to our adult 
group there were also more males than females but this difference was also not 
significant. Risk factors in the development of melanoma are; large congenital 
naevus (>2cm) which occurs in 1/20000 births and garment naevus (>20cm) 
occurring in 1/500000 births. Malignant transformation is estimated to be at about 
5%.16,17 The risk of melanoma arising in a large congenital naevus during the first 
year of life is estimated at 8.6 per 10,000.18 Therefore prophylactic excision is 
recommended for large congenital naevi.  In garment naevi, a lifelong clinical 
Time to local recurrence stage I/II
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Fig 1. Time to local recurrence of the stage I/II juvenile and control group ________________________________________                  C h a p t e r  V I 
surveillance is warranted. For small and medium sized congenital naevi (<2cm), 
treatment recommendations remain controversial.19 If removal is desired, it is 
reasonable to wait until after puberty, when the child is better able to tolerate the 
procedure, because the risk of malignancy in these lesions prior to this period is 
exceedingly small.4 Xeroderma Pigmentosum is an inherited disorder 
characterized by photosensitivity and defective cellular repair of DNA damaged 
by UV radiation. About 5% of these patients will develop melanoma at a median 
age of 19 years. Protective clothing and the use of sunscreen is recommended, and 
close monitoring of these patients is necessary at frequent intervals. A melanoma 
can develop in patients with dysplastic naevus syndrome as early as 10 years old, 
but usually they occur around the age of 1 5  d u e  t o  a n  i n c r e a s e  i n  s u n l i g h t  
exposure. The appearance of a new area of black pigmentation in a dysplastic 
naevus may be the best indicator of early malignant change.  
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Overall survival
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 exposure causes the malignant 
ansformation but recently researchers at the National Cancer Institute reported 
the most important predictors of long-term survival in young 
ile 
is is 
Historically it is believed that chronic sunlight
tr
that even a single exposure of strong sunlight during childhood can lead to 
melanoma.20  
Previous reports suggested that the thickness of the melanoma and the level 
invasion are 
patients.21,22 In our series of juvenile melanomas, we did not confirm these findings.  
Regarding DFS and OS, we demonstrated that Breslow thickness, male gender,  
tumor location (trunk), ulceration, increasing age a at diagnosis were 
p=  0 . 7 7 8
nd stage 
independent prognostic variables for the adult group. However, in the juven p = 0.464
group only the stage at diagnosis was calculated to be a prognostic factor. Th
p = 0.778
p = 0.464
an interesting find idering that in our series there was a significant 
difference in the amount of patients (27%) that presented with a locally advanced 
stage IIIB compared to the adult control group (11%). A possible explanation may 
ing cons________________________________________                  C h a p t e r  V I 
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seems to be no difference in the 10 year DFS and OS between 
e two groups even though juvenile patients presented more often with a locally 
be a delay in treatment by patient, parent or physician or even a histopathological 
misdiagnosis. Usually there is a delay in clinical diagnosis and occasionally a 
failure of the patient and/or parent to seek medical help.23,24 It is therefore 
imperative for physicians to refer these patients to a specialized center in case of 
any doubt regarding a naevus in the young for an excisional biopsy. Despite the 
amount of patients diagnosed at an advanced stage, the 10-year survival rate did 
not significantly differ between the adult and juvenile groups. We report a 10 year 
DFS of 64% for Stage I/II juvenile patients and 45% for the Stage III juvenile 
patients. A 79% 10-year OS was calculated for the Stage I/II juvenile group and 50% 
for Stage III group. Tate et al. reported comparable rates of DFS in children to those 
in adults with Stage I/II disease: approximately 77% at 5 years.25 This is accordant 
to our results at 5 years (Fig.2). In a recent population-based study in Europe the 5-
year overall survival for childhood (0-14 yrs) melanoma was 79%.5 Data available 
from the USA Surveillance, Epidemiology and End Results (SEER) shows, for the 
age group of 10-14 years, a 5-year overall survival of 86%.26 These studies are not 
entirely comparable because of the age groups studied compared to our study (10-
14yrs vs.12-19yrs).  
 
In conclusion, there 
th
advanced stage. Also the known prognostic factors do not apply for the juvenile 
patients, except for the stage at diagnosis. The factors that affect the DFS and OS 
are not yet known and further research is necessary to determine which factors are 
responsible for the course of this disease in juvenile patients. Depending upon the 
results of the Morton trial it will be clear whether there is a role for sentinel lymph 
node biopsy in these young patients. It still remains imperative that clinicians 
recognize the occurrence of this disease in younger patients and that it can follow 
an aggressive course. Prompt excision of suspected pigmented naevi is warranted 
and referral to a specialized center is justified.  _____________________________________________________________ 
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  Introduction 
 
Cutaneous melanomas are tumors with an unpredictable biological behavior. The 
worldwide incidence of melanoma is increasing dramatically and despite 
significant advances in prevention, early detection and treatment, the mortality 
rate continues to increase steadily.1-3 Currently the incidence rate and mortality rate 
in the Netherlands is respectively 12.6 and 3.1 per 100,000 people, with 2100 new 
cases of melanoma being diagnosed in 1998.4 Cutaneous melanoma of the head 
and neck region comprise 10-20% of all melanoma.5-7 Patients with head and neck 
melanoma have a worse prognosis than those with extremity or axial lesions, with 
an overall 5-year survival of approximately 65%.8 However, if local recurrence 
develops the 5-year survival drops to 36%.9  
Melanoma represents the third most common cause for the development of brain 
metastases, after primary tumors of the lung and breast.10,11 Schouten et al. 
reported an incidence of 7.4% from a cohort of melanoma patients of all stages and 
primary locations.11 The question has been risen as to if there is a difference in 
incidence in brain metastases between head and neck cutaneous melanoma and 
extremity/truncal melanoma which could explain the difference in survival 
between these two groups. As a result of the increasing number of melanoma 
cases, the incidence of brain metastases is also  l ike l y t o  in c rea se  in  t h e  c o m i n g 
decade. It has therefore become important to investigate and identify the risk 
factors associated with this devastating complication so that patients at highest risk 
can be monitored more closely and possibly treated earlier to improve the survival 
and quality of life.  
 
  Patients and Methods 
 
Between 1965 and 2000, a total of 2567 patients were diagnosed and treated for a 
cutaneous melanoma at the Groningen University Medical Center. The population 
consisted of 991 male patients (39%) and 1576 female patients (61%). During this 
period, 324 (13%) patients of which 152 female (47%) and 172 male (53%), were 
treated for a cutaneous melanoma of the head and neck. The median age was 57.5 
(range 4.3-93.5) years with a median Breslow thickness of 2.1 (range 0.1-13.0) mm. ________________________________________               C h a p t e r  V I I 
The melanomas were staged according to the 2002 American Joint Committee on 
Cancer (AJCC) staging system.12 The clinical and pathological data was retrieved 
from the Groningen melanoma database. Patients who were classified as having 
head and neck cutaneous melanomas and brain metastases were identified as the 
study group. The clinical data retrieved included gender, age at diagnosis, site of 
the primary tumor, and stage at diagnosis. The histopathological characteristics 
recorded included the histologic subtype of melanoma (superficial spreading, 
nodular or other/unknown), Breslow’s depth of invasion (in millimeters), tumor 
ulceration, the presence or absence of vascular and/or lymphatic invasion and 
mitotic rate per 5 high power fields (per mm2). All histological slides were 
reviewed at our institution.  
 
Treatment 
All patients were treated according to the guidelines of the Dutch Melanoma 
Working Party.13 Most patients, who were referred to the Groningen University 
Medical Center, underwent excision of their primary lesions elsewhere. The 
patients were referred for further treatment consisting mostly of wide excision 
only, in certain cases in combination with an elective or therapeutic lymph node 
dissection. A sentinel lymph node biopsy was performed since 1995.  
 
Follow up   
All patients were regularly followed in the outpatient clinic for regional and/or 
distant failures. The follow up included history, physical examination and yearly 
 
  Total group 
Head and Neck 
Patients 
Head and Neck 
Patients with Brain 
metastases 
Extremity / Axial 
Matched control 
group 
Total Patients  324 26  26 
Age median 
(range) 
58 
(4 – 94) years 
46 
(16 – 79) years 
54 
(24 – 76) years 
Male  172 (53%)  19 (73%)  11 (42%) 
Female  152 (47%)  7 (27%)  15 (58%) 
Table 1: Clinical data 
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chest x-rays. It did not include lab controls or regularly scheduled CT scans of the 
brain. Regional failure was defined by the histological or cytological confirmation 
of tumor cells at the site of the primary tumor and/or along its lymphatic drainage 
pathway to the first lymph node basin. Distant failure was defined by radiological 
detection of suspected lesions by means of CT (lungs, brain), ultrasound (liver) and 
bone scintigraphy. Before the introduction of these diagnostic tools, distant 
metastases were diagnosed clinically. Appropriate treatment of recurrences was 
performed depending of the type and site of recurrence. No patient received any 
kind of adjuvant systemic treatment. Patients with brain metastases were treated 
either with surgery, radiation therapy, steroids, chemotherapy or a combination of 
these. 
 
Incidence of brain metastases and matched controls  
The incidence of brain metastases for the extremity/truncal group was calculated 
by using a subgroup of patients of the database. This subgroup consisted out of 518 
males and 861 female patients and which presented which Stage I-III disease.   
A matched control analysis between the head and neck patients who did develop 
brain metastases and a match control group from the extremity/truncal melanoma 
was performed to isolate risk factors. To verify these results, we isolated these 
factors and performed the same analysis on our complete database of head and 
neck patients that did not develop brain metastases (298 pts). 
 
Statistics 
The software package SPSS 10.0 for Windows (SPSS, Inc., Chicago, IL) was used for 
statistical analysis. To calculate the difference in incidence of brain metastases the 
exact confidence interval construction was used for the test of binomial 
populations. To compare the study group and the matched control group, cross 
tables and the chi-square test were used. The logistic regression method 
(multivariate) was used to verify our results with the complete database of 
cutaneous head and neck melanoma. ________________________________________               C h a p t e r  V I I 
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Total group 
Head and 
Neck 
Patients 
Head and 
Neck Patients 
with Brain 
metastases 
Extremity / 
Axial 
Matched 
control 
group 
0 – 0.75  123 (38%)  3 (12%)  0 (0%) 
0.76 – 1.50  51 (16%)  3 (12%)  6 (23%) 
1.51 – 4.00  96 (29%)  8 (30%)  15(58%) 
> 4.01  54 (17%)  12 (46%)  5 (19%) 
Breslow 
thickness 
(mm) 
Median 
(range) 
1.3 (0.1 – 13.0)  3.3 (0.7 – 12)  2.9 (0.9 – 9.8) 
Yes  64 (20%)  10 (38%)  9 (35%) 
No  166 (51%)  13 (50%)  17 (65%)  Ulceration 
Unknown  94 (29%)  3 (12%)  0 (0%) 
SSM  80 (25%)  10 (38%)  19 (73%) 
Nodular  54 (17%)  8 (31%)  6 (23%)  Histogenesis 
Other  190 (58%)  8 (31%)  1 (4%) 
1 per 5 hpf  78 (24%)  3 (12%)  7 (27%) 
2-4 per 5 hpf  52 (16%)  7 (27%)  13 (50%) 
>5 per 5 hpf  50 (15%)  11 (42%)  6 (23%) 
Mitotic rate 
Unknown  144 (45%)  5 (19%)  0 (0%) 
Absent  205 (64%)  19 (73%)  25 (96%) 
Lymphatic  8 (2%)  1 (3%)  0 (0%) 
Blood vessel  7 (2%)  3 (12%)  1 (4%) 
Vascular 
invasion 
Unknown  104 (32%)  3 (12)%  0 (0%) 
mm: millimeter, SSM: superficial spreading melanoma, hpf: high power field  
 
Table 2: Histopathological data 
 
Disease free survival (DFS) was defined as the time between the date of diagnosis 
of the primary tumor and the date of diagnosis of brain metastases. The follow up 
time was defined as the time between the date of diagnosis and the date of disease-
specific death or last visit to the outpatient clinic. The Kaplan-Meier and Cox _____________________________________________________________ 
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regression analysis tests were performed in order calculate the DFS and the overall 
survival curves. A p-value less than 0.05 was considered to be significant. 
 
  Results 
 
Clinical and histopathological data 
Twenty-six of the 324 patients with head and neck melanoma (8%) were found to 
develop brain metastases after a median follow up period of 24 (range 4-75) 
months. The median age of the study group was 46 (range 16-79) years. The 
median total follow up time for the patients who developed brain metastases was 
2.3 yrs (range 0.6 – 11.5 yrs). Of the 26 patients, 4 were Stage I, 10 Stage II, and 12 
Stage III (specifically: 2-IA, 2-IB, 3-IIA, 4-IIB, 3-IIC, 3-IIIA, 8-IIIB, and 1-IIIC). The 
median Breslow thickness was 3.3 (range 0.7-12) mm. See Table 1 and 2 for the 
complete clinical and histopathological data of the study group, matched control 
group and total group of head and neck patients. In comparison, the incidence of 
extremity/truncal melanoma with brain metastases was 5.2% (CI 0.058-0.108, 
P<0.05). Ten of the twelve Stage III patients underwent a therapeutic lymph node 
dissection, 1 Stage IIB and 1 Stage IIC patient had an elective lymph node 
dissection and 1 Stage IIB patient underwent a sentinel lymph node biopsy. The 
treatment of brain metastases consisted out of: steroids and radiation in 9 patients 
(35%) (total 30 Gy in 10 fractions of 3 Gy), chemotherapy in 2 patients (8%) (1 
patient a combination of carboplatin and cytarabine, 1 patient a combination of 
imidazole carboxamide (DTIC), cisplatin and vinblastin), while in 2 patients (8%) 
with a single brain metastasis a metastasectomy was performed with adjuvant 
radiotherapy. Steroids alone (dexamethasone) were prescribed for the remaining 
13 patients.  
  
Time to brain metastases (DFS) and overall survival 
For the Stage I/II head and neck patients which developed a brain metastasis, the 
median time to brain metastasis was 24 (range 4 – 75) months. For the Stage III 
patients the median time was 20 (range 4 – 75) months (Figure 1). The DFS between 
Stage I/II and Stage III was not significantly different. The median survival for all 
26 patients was 2.4 (range 0.2-64.3) months, and the one-year survival was 15% ________________________________________               C h a p t e r  V I I 
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after developing brain metastases (Figure 2). The primary site of distant failure in 
the Stage I/II group was 71% (10/14) in the brain and 29% (4/14) in the lungs. For 
the Stage III patients the percentages were 59% (7/12) brain, 33% (4/12) lungs and 
8% (1/12) bone. Thirteen of the 26 patients (50%) developed multifocal brain 
metastases, 3 patients (12%) developed a single metastasis and in the remaining 10 
patients (38%) the medical records did not mention details with respect to the 
extent of the brain metastases.  
 
Prognostic factors 
From our cross-tables analysis (Table 3) it shows that the variables Breslow 
thickness, gender and mitotic rate have discriminating power between the study 
group and the match control group. The head and neck group with brain  
 
  HN + vs. ET match control  HN + vs. HN - 
  Chi- square  p- value  Chi- square  p- value 
Breslow thickness 
(>4 mm) 
 
9.01 0.029 16.5 <0.001 
Gender 
(Male) 
 
5.04 0.025 4.45  0.035 
Mitotic rate 
(>5 per 5 hpf) 
 
9.87 0.02 20.6 <0.001 
HN + : Head and neck patients with brain metastases; HN - : Head and neck patients 
without brain metastases; ET: extremity / truncal patients; mm: millimeter; hpf: high 
power field  
 
Table 3: Chi-square analysis between the head and neck group with brain metastases and 
the matched control group; and between the head and neck group with and without brain 
metastases.   
 _____________________________________________________________ 
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Fig. 1: Time to Brain metastases 
 
metastases revealed a higher score on Breslow thickness greater than 4 mm, there 
are more males and the head and neck-group has a significant higher mitotic rate 
(>5 per 5 hpf).These results were checked in a broader spectrum by performing the 
same cross tables analysis on our complete database of 298 head and neck patients. 
This analysis confirmed Breslow thickness greater than 4 mm, male gender and 
mitotic rate as prognostic factors for developing brain metastases (Table 3). 
Subsequently the logistic regression analysis with these variables revealed that 
besides the variables Breslow, mitosis and gender, younger age (p<0.05) entered as 
an additive variable (Table 4).  
 
  Discussion 
 
The incidence of brain metastases from cutaneous head and neck melanoma has 
been hypothesized to be higher than trunk or extremity melanomas. The incidence 
of brain metastases from head and neck melanoma was in this series 8% vs. 5.2% 
from the extremity/truncal melanoma (Stage I-III). To our knowledge, only two 
other clinical series have previously reported data on this subject. These authors  
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Fig. 2: Overall survival after developing brain metastases 
 
reported an incidence of 11% metastases to the central nervous system from all 
head and neck melanoma cases (Stage I-IV).10,14Furthermore, they claim that 19.6% 
of all metastases to the central nervous system from melanoma cases originate 
from the head and neck region. Van de Vrie reported that more than 40% of the 
patients with loco-regionally metastasized melanoma (Stage III) of the head and 
neck region developed cerebral metastases. They therefore recommend a 
neurological examination and a CT scan of the brain prior to a lymph node 
dissection.15 In our series, from the 95 head and neck melanoma patients who 
presented as Stage III or became Stage III from Stage I, 19 (20%) patients developed 
brain metastases. An interesting observation is that in most of the patients that did 
develop brain metastases, this was also the primary site of distant failure 
suggesting a clear affinity for this pathway of dissemination.  The most common 
symptoms of brain metastases were headaches, unsteadiness, nausea, cranial nerve 
palsy and disorientation due to increased intracranial pressure or local pressure on 
the affected structure. The median interval time from excision of a histologically 
confirmed primary lesion to a diagnosis of brain metastases was 24 months in the 
Stage I/II patients and 20 months in the Stage III patients with the longest interval 
being 75 months. Retsas et al. reported similar interval times of 29.6 months to 
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brain metastases from all cutaneous melanoma.16 Our results show a median 
overall survival of 2.4 months and a 1-year survival of 15% after developing brain 
metastases which is comparable with a previous report published by Sampson et 
al.14 The most significant factor influencing survival of patients with brain 
metastases is the number of other involved organs with metastatic disease. 
Consistently, Stage IV patients with metastases limited to the brain have had a 
significantly better outcome.14,17-19  
As can be seen from our results, a Breslow thickness greater than 4 mm and a 
higher mitotic rate (>5 per 5 hpf) increases the risk of the patient falling into the 
risk group of developing brain metastases. It is well accepted in the literature, that 
increasing Breslow thickness and increasing mitotic rate, have a negative effect on 
disease free and overall survival.12,20,21  It is therefore that Breslow thickness has 
been included as an independent prognostic factor in the new American Joint 
Committee on Cancer staging system. However the other main prognostic factor, 
tumor ulceration, was not found to be a determining factor in our study in 
developing brain metastases. Other known prognostic factors such as nodular 
tumor type and vascular invasion were also not determining factors of developing  
Variable  Regression coefficient (ß)  P value 
Breslow thickness  0.59 0.012 
Mitotic rate  0.459 0.020 
Gender  -0.837 0.084 
Age  -0.24 <0.05 
R2 (explained variance) = 0.21 (p<0.01)  
Table 4: Variables associated with brain metastases from HN melanoma (Multivariate 
regression analysis) 
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brain metastases. This last one is surprising considering that the primary site of 
distant failure in all stages was the brain, which by definition is a hematogenous 
spread. Our results also showed that is not so much being male that has an added 
risk on the development of brain metastases, but that being female has a protective 
effect against the development of brain metastases. Similarly being older also had a 
protective effect. Based on the current findings, clinicians should be aware of the 
increased risk of male patients and younger patients of developing brain 
metastases compared to the female and older patient.  
It has been previously reported that patients who develop single brain metastasis 
have a better overall survival than patients with multiple brain metastases. Two 
prospective randomized clinical trials by Patchell and Vecht, in which patients 
with single metastases and stable extra cranial disease were treated either with 
surgery followed by radiotherapy or radiotherapy alone, showed a significant 
lower recurrence rate and longer overall survival in the surgical group.22,23 These 
trials however included mostly primarily nonsmall-cell lung cancer as the primary 
tumor and involved only nine patients with metastatic melanoma. The question 
still remains if this data is applicable for melanoma metastasis alone. The current 
literature does seem to suggest that surgical resection for single or limited brain 
metastasis, which could be easily resected prolongs the disease free interval and 
overall survival when extra cranial tumor is absent or stable during the last three 
months.24,25 From our 26 patients which developed brain metastases, the only 
patient surviving had a single metastasis which was surgically resected followed 
by adjuvant radiotherapy. In recent years, gamma knife stereotactic radiosurgery 
has gained considerable momentum as a major alternative in the management of 
intra-cranial metastatic melanoma in selected cases.19,26,27 And whole brain 
irradiation alone has proven to be a useful therapy in the palliative setting.28 The 
role of chemotherapy for brain metastases is limited and still controversial. 
Melanoma is traditionally not a very chemosensitive disease. Adding to that, 
limited life expectancy and presence of the blood-brain barrier have been 
considered contraindications for relatively aggressive therapies such as 
chemotherapy. There is therefore no standard chemotherapeutic treatment for 
Stage IV disease. In the Netherlands, Stage IV patients are usually treated in 
clinical trials if possible. If not possible then the patient can be treated with DTIC.29 
Newer drugs such as topotecan and temozolomide seem to be particular promising _____________________________________________________________ 
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(alone or in combination with other drugs) in the treatment of brain metastases 
from cutaneous melanoma.30  
 
In conclusion, brain metastasis develops in 8% of all head and neck melanoma 
cases compared to 5.2% from extremity/truncal melanoma. Breslow thickness, 
mitotic rate, male gender and younger age have been isolated to be risk factors in 
developing brain metastases in head and neck melanomas. The reason why the 
head and neck melanomas with these characteristics primarily disseminate to the 
brain so frequently is still unclear. The head and neck region is of course more 
exposed to sunlight and has a rich amount of lymphatic vessels. But these factors 
are not determining in the development of a hematogenous spread such as to the 
b r a i n .  F u r t h e r  r e s e a r c h  i s  n e c e s s a r y  t o  u n v e i l  t h i s  s p e c i f i c  p a t h w a y  o f  
dissemination. The current literature suggests that surgical resection followed by 
radiotherapy for limited metastasis may prolong survival and the quality of life. ________________________________________               C h a p t e r  V I I 
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  Part A   Hyperthermic Isolated limb perfusion 
 
The theory behind the delivery of isolated regional chemotherapy is that a high 
drug uptake by the tumor may be achieved with higher doses of chemotherapeutic 
agents without increasing the systemic toxicity. The technique of isolated limb 
perfusion, a regional cancer treatment that allows the direct infusion of high doses 
of chemotherapeutic agents in the arterial supply of a tumor-bearing area of a limb, 
came available with the development of an extra-corporeal circuit for cardiac 
surgery (chapter 2). In the mid fifties the surgical-oncologists Creech and 
Krementz of the Tulane University in New Orleans developed the technique of the 
isolated limb perfusion. The first isolated limb perfusion was performed at the 
Groningen University Medial Center in 1964. In the sixties Cavaliere reported on 
selective heat sensitivity of tumor cells and added hyperthermia within the 
regional perfusion technique. Key point in isolated limb perfusion is that the dose 
of chemotherapeutic agents used, can be 15-20 fold the maximum systemic 
tolerated dose, since vital organs are isolated from the perfusion circuit. In the 
beginning isolated limb perfusion was used as a therapeutic treatment for locally 
advanced melanoma, recurrences and/or intransit metastases. Later on adjuvant 
limb perfusions were introduced in the treatment of melanoma of the limb, but an 
EORTC randomized multi center trial showed no real benefit of hyperthermic 
isolated limb perfusion as an adjuvant treatment modality for patients with high-
risk stage I melanoma (> 1.5 mm Breslow thickness). On the other hand isolated 
regional perfusion with melphalan is a well accepted treatment for intransit 
metastases and/or recurrences in patients who are no longer candidates for local 
treatment, e.g. surgery, cryotherapy or laser treatment. Other chemotherapeutic 
agents have been used in melanoma perfusions, showing lower subjective response 
rates and often higher toxicity. A variety of other antineoplastic agents besides 
melphalan have been used during the last forty years in hyperthermic isolated 
limb perfusion such as darcarbazide (DTIC), actinomycin-D, thiotepa, mitomycine-
C, doxorubicin and more recently cisplatin. The majority of the cytostatic agents 
were or ineffective, or the duration of response quite limited, or when a drug 
showed effectiveness the local toxicity hampered the further application. 
Doxorubicine showed effectiveness but disturbed the arterial vascularity of the ________________________________________             C h a p t e r  V I I I 
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limb, while cisplatin was too neurotoxic. In the late nineties Lejeune introduced 
TNFα in the perfusion setting together with melphalan in the treatment of locally 
advanced melanoma and sarcoma of the limb. In a randomized trial between 
melphalan and TNFα with melphalan for locally advanced melanoma, no real 
benefit was seen by including TNFα, compared to melphalan alone with a median 
survival of 2.5 years. Patients with low tumor burden or small tumors showed 
equivalent results (TNFα and melphalan versus melphalan), while TNFα and 
melphalan showed higher response rates in bulky melanoma. Therefore melphalan 
is the drug to be used in melanoma perfusion and combined with TNFα when 
bulky disease or recurrent disease after previous melphalan perfusion is the 
indication for perfusion.  
 
In chapter 3 a derivative of cisplatin, carboplatin was used in a feasibility study 
with regard to effectiveness and toxicity in the management of locally recurrent 
and/or intransit metastases of melanoma or locally advanced soft tissue sarcoma.  
Three patients, two with locally advanced melanoma and one with a low grade  
liposarcoma of the lower extremity, were treated with ILP under mild 
hyperthermia (39 - 40￿ C) with 125 mg carboplatin/L perfused limb volume. No 
systemic toxicity was observed. Local toxicity consisted of postperfusion edema 
present in all 3 patients which resolved within 2 weeks. Clinically a persistent local 
neuropathy was observed in all 3 patients, 2 of which were confirmed by 
electromyogram and nerve conduction study. The severe motor-sensory 
neuropathy was located mainly in the peroneal and sural nerves of the perfused 
limbs. Pharmacokinetic parameters of the carboplatin showed a higher 
concentration of carboplatin in the skin compared to the muscle. The two 
melanoma patients showed a complete response but developed local recurrences 
within 12 months after popliteal and femoral perfusion. The third patient 
underwent a delayed excision of the sarcoma 8 weeks after perfusion which 
revealed 50% viable tumor. One of the melanoma patients and the sarcoma patient 
died from lung metastases respectively 56 and 31 months postperfusion treatment. 
The other melanoma patient is alive 95+ months post perfusion treatment. We 
concluded that the local neurotoxicity observed did not warrant further research of 
carboplatin in ILP.  
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With the introduction of recombinant tumor necrosis factor α (TNFα) in the early 
nineties, the effectiveness of the ILP was increased for melanoma and especially for 
STS patients. However, leakage of TNFα into the systemic circulation gives rise to 
more severe side effects than melphalan alone. A 1% leakage may already result in 
hypotension of the patient and a 10% leakage of TNFα can cause a potentially fatal 
septic shock like syndrome. However, strict isolation of the limb is not always 
achievable due to anatomical variations and/or technical reasons. Minimal 
systemic leakage can therefore not always be prevented, and makes continuous 
leakage monitoring during the perfusion procedure of utmost importance. In the 
period 1977 – 1991, 331 perfusions were performed at this institution with a 
median leakage of 8.0% (range 0 – 30%) using melphalan. In chapter 4 we 
calculated our leakage of perfusate into the systemic circulation using radioactive 
tracers in the patients who were perfused after 1991. Coincidentally since 1991, the 
very toxic TNFα has been added to the treatment regimen for ILP. The aim of the 
study was to assess the changes in leakage rate between the periods of 1977-1991 
and 1991-2000 and to determine the factors responsible for these changes. One 
hundred and nineteen patients underwent ILP mainly for locally recurrent 
melanoma or locally advanced soft tissue sarcoma. ILP was performed with 
melphalan (33%) or in combination with TNFα (65%). There were 67 iliacal (56%), 
12 femoral (10%), 25 popliteal (21%) and 15 axillary (13%) perfusions performed. 
Leakage to the systemic circulation was monitored continuously with the help of 
131I-albumin and a stationary scintillation detector placed above the heart. The 
median maximum leakage was 2.7% (range 0-21%) which is significantly less than 
the previous period of 1977-1991 where leakage of 8% (0-30%) was previously 
reported (P<0.05). A statistical difference of the leakage was detected between the 
levels of perfusion were the iliacal and femoral levels showed more leakage than 
the axillary and popliteal levels (P<0.05). Furthermore when TNFα was used, there 
appeared to be significant less leakage than when melphalan was the sole drug 
(P<0.05). We concluded that nowadays leakage from isolated perfusions into the 
systemic circulation is further minimized compared to the days when melphalan 
was the sole drug used. Increased awareness for TNFα leakage, continuous 
external monitoring with 131I-albumin as the main isotope, flow rate regulation in 
the perfusion circuit and regulation of the systemic blood pressure of the patient 
have all been major contributors to this improvement. ________________________________________             C h a p t e r  V I I I 
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  Part B   Uncommon aspects of melanoma 
 
Pregnancy 
Melanoma is often diagnosed in young adults and a significant number of these 
patients are women in their reproductive phase of life. The real incidence of 
melanoma during pregnancy is unknown. It has been suggested that women who 
present with a melanoma during pregnancy have a worse prognosis due to a more 
aggressive behavior of the melanoma due to an influence of hormonal or 
reproductive factors. In chapter 5 the aim of the study was to evaluate the long-
term effect of pregnancy on the progression of the disease in Stage I/II melanoma. 
During the period 1965-2001, 46 pregnant women were treated for a Stage I/II 
melanoma. These patients were compared with an age-sex control (non-pregnant) 
group of 368 Stage I/II patients. The patients were staged according to the 2002 
AJCC TNM melanoma staging system. The 10-year disease free survival (DFS) and 
10-year overall survival (OS) were calculated using the logistic regression method. 
The median age for the pregnant patients was 30 (range 18-46) years and 36 (range 
17-45) years for the non-pregnant patients. Median follow-up time was 109 (range 
1-356) months. Pregnant patients presented more often with thicker melanomas 
(median 2.0 vs. 1.7 mm, ns). No difference in tumor location, histologic subtype, 
tumor ulceration and vascular invasion could be detected between the pregnant 
and non-pregnant group. There was no statistical difference in the 10-year DFS and 
the 10-year OS between the 2 groups. The 10-year DFS for the pregnant patient and 
non-pregnant group was respectively 88% vs. 86% for the Stage I patients, and 67% 
vs. 73% for the Stage II patients. The 10-year OS was respectively 94% vs. 90% for 
the Stage I patients and 82% vs. 81% for the Stage II patients. We conclude that 
pregnancy does not appear to adversely affect long-term survival in patients with 
clinically localized melanoma. 
 
Childhood and Juvenile melanoma 
Melanoma before puberty is rare, but the incidence increases steadily thereafter in 
each decade. The steepest trends of increasing incidence are in those aged over 65 
and the lowest trends are in the younger age groups. Approximately 1 to 4% of all 
new melanoma cases occur in patients under the age of 20 years and only 0.3% _____________________________________________________________ 
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among those younger than 14 years. In chapter 6 we analyzed the childhood and 
juvenile melanomas treated at our institution with a special focus on differences in 
clinical characteristics, prognostic factors, disease free and overall survival in 
comparison with those of adults. During the period 1965-2003, 55 patients under 
the age of 19 years (26 female (47%) and 29 male (53%)), were treated for a 
cutaneous melanoma. These patients were compared with an adult control group 
of 972 patients. The patients were staged according to the 2002 AJCC TNM 
melanoma staging system. Using logistic regression analyses, the 10-year disease 
free survival (DFS), 10-year overall survival (OS) and independent prognostic 
factors determining OS and DFS were calculated for the juvenile as for the adult 
group. Six patients were under the age of 12 and therefore not considered for 
statistical analysis. The median age for the juvenile patients was 17 (range 12 - 19) 
years and 49 (range 20 – 93) years for the adult control patients. Median follow-up 
time was 92 (range 4 - 366) months. The Breslow thickness was comparable in both 
groups (juvenile median 1.6 mm vs. adult 2.0 mm, p=0.075). Juvenile patients did 
present more often with locally advanced melanoma (p<0.01). With regard to the 
DFS and OS, increasing age, mitotic rate, ulceration, Breslow thickness, male 
gender and stage at diagnosis all were calculated to be independent prognostic 
factors for the adult group. Where as in the juvenile group only the stage at 
diagnosis was a significant factor. There was no statistical difference in the 10-year 
DFS and the 10-year OS between the 2 groups. The 10-year DFS for the juvenile 
patients and adult group was respectively 64% vs. 71% for the Stage I/II patients, 
and 45% vs. 40% for the Stage III patients. The 10-year OS was respectively 79% vs. 
83% for the Stage I/II patients and 50% vs. 50% for the Stage III patients. We 
concluded that there is no difference in the 10 year DFS and OS between the two 
groups even though juvenile patients presented more often with a locally 
advanced stage. Also the known prognostic factors do not apply for the juvenile 
patients, except for the stage at diagnosis. These factors are not yet known and 
further research is necessary to determine which factors are responsible for the 
course of this disease in juvenile patients. 
 
Brain metastases from Head and Neck melanoma 
There is an increasing incidence of cutaneous melanoma (CM), and 20-25% of CM 
is located in the head and neck region. In chapter 7 the incidence of brain ________________________________________             C h a p t e r  V I I I 
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metastases, risk factors and outcome were analyzed for the melanomas originating 
in the head and neck region. During the period 1965-2000, 324 patients of which 
152 female (47%) and 172 male (53%), were treated at the GUMC for a CM of the 
head and neck. The patients were staged according to the 2002 AJCC melanoma 
staging system. A matched control analysis was performed in order to identify the 
risk factors for the occurrence of brain metastases. The analysis was performed 
using cross tabulations, chi-square test and logistic regression method. Twenty six 
(8%) HN compared to 5.2% (CI 0.058 – 0.108, P<0.05) of the extremity/ truncal 
patients developed brain metastases. The 26 head and neck patients (4 Stage I , 10 
Stage II, and 12 Stage III) had a median age of 46 (range 16-79) years and 
developed brain metastases after a median follow up of 24 (range 4-75) months. 
The median Breslow thickness was 3.3 (range 0.7-12) mm. The patients were 
treated either with steroids, surgery, radiation, chemotherapy or a combination of 
these. The median survival after developing brain metastases was 2.4 (range 0.2-
64.3) months with a one-year overall survival of 15%. Risk factors identified for 
developing brain metastases from head and neck melanoma are younger age, male 
gender, Breslow thickness greater than 4 mm and mitotic rate.  
In conclusion, head and neck CM tend to develop brain metastasis in 8% compared 
to 5.2% in extremity/ truncal melanoma and is associated with the above 
mentioned prognostic factors. The prognosis of these cases is extremely poor with 
the available therapies. Metastasectomy and adjuvant irradiation for a single brain 
metastasis may prolong survival in selected cases. 
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  Conclusions 
 
•  Hyperthermic Isolated limb perfusion with melphalan has evolved to be 
an accepted palliative treatment for intransit metastases and/or recurrences 
in patients who are no longer candidates for local surgical treatment. 
•  Hyperthermic Isolated limb perfusion with carboplatin has proven to be 
ineffective in treating locally advanced melanoma and is accompanied by a 
severe neurotoxicity to the perfused limb. 
•  Continuous external monitoring with 131I-albumin as the main isotope is a 
reliable method for detecting leakage of the perfusate to the systemic 
circulation. 
•  Pregnancy does not adversely affect the long-term outcome in patients 
who are diagnosed with a primary Stage I or II melanoma.  
•  The long term outcome of children/juvenile melanoma is comparable with 
that of adults. However, besides the stage of the disease at presentation, 
the known prognostic factors do not seem to apply for the 
children/juvenile melanoma.   
•  There is an increase in brain metastases from cutaneous head and neck 
melanoma compared to extremity/truncal cutaneous melanoma.  ________________________________________             C h a p t e r  V I I I 
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  Future Perspectives 
 
Although conventional ILP is an effective method for treating recurrent limb 
melanoma, it is a complex and invasive procedure. Patient selection is rigorous and 
many patients can therefore not be treated. Patients with systemic metastases as 
w e l l  a s  l i m b  r e c u r r e n c e s ,  o r  p a t i e n t s  w i t h  m e d i c a l  c o - m o r b i d i t i e s  w e r e  u s u a l l y  
excluded from ILP therapy. Since 1994 the Sydney melanoma unit introduced a 
simplified form of ILP called isolated limb infusion (ILI). This new technique was 
in fact a low-flow ILP performed under hypoxic conditions via small caliber 
arterial and venous catheters which are inserted percutaneously via the 
contralateral groin. Because of its low-pressure system, a pneumatic tourniquet is 
sufficient to control the leakage of the drugs into the systemic circulation. It is 
however not possible to raise the limb temperature above 38.5° C. The ILI 
procedure has been shown to be of similar efficacy to ILP and can be used in the 
elderly and medically compromised patients. Furthermore, the procedure can be 
repeated and systemic metastases are not an exclusion criteria.    
Cutaneous melanoma is presently still an aggressive disease with an unpredictable 
biological behavior. The only curative treatment consists of radical surgical therapy 
of the primary tumor including its metastatic deposits. In the forthcoming years 
the value of the sentinel lymph node biopsy will become clear which role it will 
occupy in the treatment of Stage I melanoma (MSLT I and II study). Also it will 
become clear if the whole-body CT or PET scan has any value in further 
(up)staging the clinically Stage III patients (OMSPECT study). For the treatment of 
Stage III and IV patients, the polyvalent melanoma vaccination is being researched 
for its effectiveness. The value of frequent and long term outpatient visits in the 
follow up will be investigated for its effectiveness (MELFON study). All of the 
above mentioned studies are supposed to improve the treatment of melanoma 
patients who are condemned with this devastating disease.    _____________________________________________________________ 
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  Hyperthermische Geïsoleerde Ledemaat Perfusie 
 
Het doel van geïsoleerde, regionale toediening van hoge doses chemotherapie is 
een versterkte cytostaticum opname in de tumor, zonder systemische toxiciteit te 
genereren. De mogelijkheid van geïsoleerde ledemaat perfusie (ILP), een vorm van 
regionale kankerbehandeling door infusie van hoge doses chemotherapeutica in de 
arteriële aanvoer van een ledemaat, kwam beschikbaar met de ontwikkeling van 
de extra-corporele circulatie ten behoeve van de hartchirurgie (hoofdstuk 2). De 
t e c h n i e k  v o o r  d e  g e ï s o l e e r d e  l e d e m a a t  p e r f u s i e  w e r d  m i d d e n  j a r e n  v i j f t i g  
ontwikkeld door de chirurgisch oncologen Creech en Krementz van de Tulane 
Universiteit te New Orleans. In het Academisch Ziekenhuis Groningen werd de 
eerste ledemaat perfusie in 1964 met succes uitgevoerd. In de zestiger jaren maakte 
Cavaliere melding van de preferentiële gevoeligheid van tumor cellen voor 
warmte, op grond waarvan hyperthermie aan de regionale perfusie techniek werd 
toegevoegd. Centraal bij de ILP staat dat concentraties tot 15 á 20 keer de maximale 
systemisch getolereerde concentratie van chemotherapeutica bereikt kunnen 
worden, aangezien vitale organen buiten de geperfundeerde circulatie liggen. Ten 
tijde van de introductie, werd de geïsoleerde ledemaat perfusie gebruikt voor 
lokaal uitgebreide melanomen, tumor recidieven en/of intransit metastasen. Na 
verloop van tijd werden ledemaat perfusies ook ingezet in de adjuvante 
behandeling van melanomen van extremiteiten. Een gerandomiseerde multi-center 
onderzoek onder EORTC auspiciën toonde geen voordeel aan van 
hyperthermische geïsoleerde ledemaat perfusies in de adjuvante behandeling voor 
patiënten met een hoog-risico stadium I melanoom (>1,5 mm Breslow dikte). 
Daarentegen is de geïsoleerde ledemaat perfusie met melfalan een erkende 
behandeling voor intransit metastasen en/of recidieven bij patiënten die niet in 
aanmerking komen voor een lokale behandelingvorm als chirurgie, cryotherapie of 
laserbehandeling. Ook andere chemotherapeutische middelen zijn gebruikt bij de 
perfusie van melanomen, maar deze hebben inferieure anti-tumor activiteit tegen 
veelal hogere toxiciteit. Gedurende de afgelopen veertig jaar heeft een scala aan 
alternatieve middelen de revue gepasseerd, waaronder dacarbazide (DTIC), 
actinomycine-D, thiotepa, mitomycine-C, doxorubicine en meer recent, cisplatine. 
De meerderheid van deze cytostatica was óf ineffectief, óf de responsduur was 
kort, óf lokale toxiciteit verhinderde verdere toepassing. Zo heeft doxorubicine wél ________________________________________                  C h a p t e r  I X 
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antitumor activiteit maar ook een scleroserend effect op de arteriën van het 
ledemaat, terwijl cisplatine te neurotoxisch is. Eind negentiger jaren werd TNFα in 
de perfusie geïntroduceerd door Lejeune, in combinatie met melfalan, in de 
behandeling van lokaal uitgebreide melanomen en sarcomen van ledematen. Uit 
een gerandomiseerd onderzoek tussen melfalan alleen en TNFα met melfalan voor 
patiënten met geavanceerde melanoom, bleek de toevoeging van TNFα geen 
duidelijk voordeel te brengen. Bij patiënten met een beperkte tumoruitbreiding of 
met kleine tumoren maakt het voor de respons geen verschil of TNFα met melfalan 
of melfalan alleen wordt gebruikt, terwijl de combinatie TNFα en melfalan wél een 
betere tumor respons geeft bij patiënten met lokaal uitgebreide melanomen. 
Vanwege deze bevindingen wordt melfalan gebruikt bij melanoom-perfusies en 
wordt alleen gecombineerd met TNFα in geval van uitgebreide ziekte óf bij 
recidieven na voorafgaande melfalan-perfusies. 
 
In hoofdstuk 3 wordt de effectiviteit en toxiciteit van carboplatine beschreven, een 
afgeleide van cisplatine, toegepast bij de perfusie van lokale recidieven en/of 
intransit metastasen van melanomen of lokaal uitgebreide weke-delen sarcomen. 
Drie patiënten, twee met lokaal uitgebreide melanomen en één patiënt met een 
laaggraadig liposarcoom van het been, werden behandeld met ILP onder milde 
hyperthermie (39-40°C) met 125 mg carboplatin per liter geperfundeerd 
ledemaatvolume. Er werd geen systemische toxiciteit waargenomen. Lokale 
toxiciteit bestond uit postperfusie oedeem en werd bij alle drie patiënten 
geobserveerd, maar verdween binnen twee weken. Persisterende lokale 
neuropathie werd geobserveerd bij alle drie patiënten en bij twee van hen werd dit 
geobjectiveerd met electromyografie en zenuwgeleidingsonderzoek. Ernstige 
senso-motorische neuropathie was aanwezig, v o o r a l  i n  d e  p e r o n e a l e  e n  s u r a l e  
zenuwen van de geperfundeerde ledematen. Bij pharmacokinetische analyse bleek 
de carboplatin-concentratie in de huid veel hoger dan in spierweefsel. De twee 
patiënten met een melanoom hadden een volledige tumor respons, maar beiden 
kregen een lokaal recidief binnen 12 maanden na popliteale en femorale perfusie. 
De derde patiënt onderging excisie van het sarcoom, acht weken na de perfusie. 
Maar bij histopathologisch onderzoek van het resectiepreparaat werd nog 50% 
vitaal tumorweefsel waargenomen. Eén patiënt met een melanoom en de patiënt 
met het sarcoom overleden ten gevolge van longmetastasen na respectievelijk 56 _____________________________________________________________ 
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en 31 maanden na de perfusie behandeling. De tweede patiënt met een melanoom 
was in leven na 95 maanden na perfusie. Lokale neurotoxiciteit staat verdere 
toepassing van carboplatine bij ILP in de weg. 
 
Met de komst van recombinant TNFα begin jaren negentig werd de effectiviteit 
van ILP voor patiënten met melanomen en vooral weke-delen sarcomen verbeterd. 
Echter, met lekkage van het TNFα naar de systemische circulatie traden ernstiger 
bijwerkingen op dan voorheen met het gebruik van melfalan alleen. Een lekkage 
van 1% TNFα kan reeds tot hypotensie leiden en een lekkage van 10% kan een 
potentieel lethaal beeld van septische shock induceren. Helaas is volledige isolatie 
van het ledemaat niet altijd mogelijk vanwege anatomische variaties en/of 
technische redenen. Daarom kan een geringe mate van lekkage niet altijd worden 
voorkomen en is continue lekkagemeting tijdens de perfusie procedure van het 
grootse belang. In de periode 1977-1991 werden 331 melfalan perfusies uitgevoerd 
in het GUMC, met een mediane lekkage van 8,0% (spreiding 0-30%).  
In hoofdstuk 4 wordt een overzicht gegeven van de gemeten lekkagepercentages 
naar de systemische circulatie met behulp van radioactieve tracers in de patiënten 
die geperfundeerd werden vanaf 1991. Het jaar 1991 valt ook samen met het 
moment van introductie van het uiterst toxische TNFα aan de ILP procedure. Het 
doel van dit onderzoek was om verschillen in de mate van lekkage tussen de 
periode 1977-1991 en 1991-2000 te achterhalen en daarvoor verklaringen te vinden. 
Honderd-negentien patiënten ondergingen ILP, hoofdzakelijk voor lokale 
recidieven van melanomen en voor lokaal uitgebreide weke-delen sarcomen. ILP 
werd verricht met melfalan alleen (33%) of in combinatie met TNFα (65%). Er 
werden 67 iliacale, 12 femorale, 25 popliteale en 15 axillaire perfusies uitgevoerd. 
Lekkage naar de systemische circulatie werd continu gemeten met behulp van 131I-
albumine via een stralingsmeter die vast boven het hart was geplaatst. Met een 
mediane lekkage van 2,7% (spreiding 0-21%) was er sprake van een significante 
daling ten opzichte van de voorgaande periode 1977-1991, met destijds 8,0% (0-
30%) lekkage (P<0,05). Een significant statistisch verschil was er ook voor het 
niveau van de perfusies, waarbij iliacale en femorale perfusies een sterkere mate 
van lekkage vertoonden dan axillaire en popliteale perfusies (P<0,05). Bijkomstig 
bleek dat wanneer TNFα was gebruikt, er significant minder lekkage was ten 
opzichte van de perfusies met melfalan alleen (P<0,05). ________________________________________                  C h a p t e r  I X 
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We stelden vast dat tegenwoordig minder lekkage wordt bereikt in vergelijking 
met de periode dat alleen melfalan werd gebruikt. Bekend met de gevaren van 
TNFα lekkage, continue uitwendige lekkage-meting met 131I-albumine als 
belangrijkste radioactieve tracer, bloedstroom-regulatie in de perfusie circulatie en 
regulatie van de bloeddruk in de patiënt zijn allen belangrijke oorzaken voor deze 
verbetering. 
 
  Ongebruikelijke aspecten van melanomen 
 
Zwangerschap 
Melanomen worden frequent gediagnostiseerd bij jong volwassenen en een 
aanzienlijk deel van hen zijn vrouwen in de fertiele levensfase. De exacte incidentie 
van melanomen gedurende zwangerschap is niet bekend. Er wordt gesuggereerd 
dat zwangere vrouwen een slechter prognose hebben ten gevolge van een 
agressiever biologisch gedrag van het melanoom door hormonale of reproductieve 
factoren.  Hoofdstuk 5 heeft ten doel om het lange-termijn effecten van 
zwangerschap op de progressie van stadium I/II melanomen te evalueren. Van 
1965 tot 2001 werden 46 zwangere vrouwen behandeld voor een stadium I/II 
melanoom. Deze patiënten werden vergeleken met een groep van 368 niet-
zwangere patiënten met stadium I/II tumoren, gecorrigeerd voor leeftijd en 
geslacht. Patiënten werden gestadieerd volgens het 2002 AJCC TNM systeem. De 
10-jaars ziektevrije overleving (DFS) en de 10-jaars overleving (OS) werden 
berekend met de logistische regressie methode. De mediane leeftijd voor de 
zwangeren was 30 (spreiding 18-46) jaar en 36 (spreiding 17-45) jaar voor de niet-
zwangeren. De mediane follow-up bedroeg 109 maanden. Zwangeren 
presenteerden zich vaker met dikkere melanomen  (mediaan 2,0 mm versus 1,7 
mm, ns). Er werd geen verschil in tumor-localisatie, histologisch subtype, tumor 
ulceratie en vasculaire invasie waargenomen tussen de zwangere en niet-zwangere 
groep. Evenmin was er een statistisch significant verschil in 10-jaars DFS en 10-
jaars OS tussen beide groepen. De 10-jaars DFS voor zwangeren en niet-zwangeren 
was respectievelijk 88% en 86% bij stadium I ziekte, en 67% versus 73% voor 
stadium II patiënten. De 10 jaars OS was respectievelijk 94% versus 90% voor 
stadium I en 82% versus 81% voor stadium II. Concluderend wordt gesteld dat _____________________________________________________________ 
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zwangerschap de lange-termijn overleving van patiënten met melanomen in een 
beperkt ziektestadium niet ongunstig beïnvloedt.  
 
Kinder en juveniele melanomen 
Het ontstaan van melanomen vóór de puberteit is zeldzaam, maar de incidentie 
stijgt met de leeftijd. De sterkste stijging in incidentie wordt waargenomen bij 
patiënten boven de 65 jaar, tegen een meer gematigde stijging bij jongeren. Circa 1 
tot 4% van alle nieuwe gevallen van melanomen wordt gevonden bij patiënten 
onder de leeftijd van 20 jaar en slechts 0,3% bij patiënten jonger dan 14 jaar. In 
hoofdstuk 6 worden het kinderleeftijd en juveniele melanoom geanalyseerd, die in 
het GUMC zijn behandeld; de klinische karakteristieken, prognostische factoren, 
ziektevrije en totale overleving werden vergeleken met tumoren bij volwassenen. 
Gedurende 1965 tot 2003 werden 55 patiënten onder de 19 jaar behandeld voor een 
cutaan melanoom. Vergelijking vond plaats met een controlegroep van 972 
volwassen patiënten. Patiënten werden gestadieerd volgens het 2002 AJCC TNM 
melanoom stadiëringssysteem. De 10-jaars DFS en de 10-jaars OS werden berekend 
met logistische regressie; onafhankelijke prognostische factoren voor OS en DFS 
werden aanvullend geanalyseerd. Zes patiënten waren jonger dan 12 jaar en 
daarmee uitgesloten van statistische analyse. De mediane leeftijd voor juveniele 
patiënten was 17 jaar, tegen 49 jaar voor de controlegroep. Er was een mediane 
follow-up van 92 maanden. Beide groepen hadden een vergelijkbare Breslow dikte 
(juveniele groep 1,6 mm versus volwassen groep 2,0 mm; P=0.075). Juveniele 
patiënten presenteerden zich vaker met lokaal uitgebreide melanomen (P<0,01). 
Leeftijd, mitose ratio, ulceratie, Breslow dikte, mannelijk geslacht en stadium bij 
diagnose bleken allen onafhankelijke prognostische factoren in de volwassen 
groep. Bij de juveniele groep daarentegen was alleen stadium bij diagnose een 
significante factor. Er werd geen statistisch verschil in de 10-jaars DFS en 10-jaars 
OS gevonden tussen de twee groepen. De 10-jaars DFS voor de juveniele en de 
volwassen groep was respectievelijk 64% en 71% voor stadium I/II, en 45% en 40% 
voor stadium III. De 10-jaars OS was respectievelijk 79% en 83% voor stadium I/II 
en 50% en 50% voor stadium III. Er is geen verschil in 10-jaars DFS en OS tussen de 
twee groepen, al presenteerden de juveniele patiënten zich wel vaker in een verder 
gevorderd ziektestadium. ________________________________________                  C h a p t e r  I X 
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Behalve stadium bij diagnose, lijken de tegenwoordig toepaste prognostische 
factoren niet te gelden voor juveniele patiënten. Welke prognostische factoren bij 
hen spelen is onbekend, zodat aanvullend onderzoek nodig is om factoren die het 
beloop bepalen bij juveniele patiënten te identificeren. 
 
Hersenmetastasen van cutane hoofd hals melanomen 
Er is een stijgende incidentie van het aantal cutane melanomen (CM), waarvan 10-
20% in het hoofd/hals gebied optreedt. In hoofdstuk 7 worden de incidentie van 
hersenmetastasen, risicofactoren en uitkomst geanalyseerd van melanomen die 
zich in het hoofd/hals gebied presenteren. In de periode 1965 tot 2000 werden 324 
patiënten (152 vrouwen en 172 mannen) behandeld in het GUMC voor een CM van 
het hoofd/hals gebied. Patiënten werden gestadieerd volgens het 2002 AJCC 
melanomen stadiëringgssysteem. Om risicofactoren te identificeren, werd een 
matched control analyse verricht. Dit werd gedaan met gebruikmaking 
kruistabellen, chi-kwadraat toetsen en logistische regressie analyse. Zesentwintig 
patiënten (8%) met hoofd/hals tumoren in vergelijking met 5,2% 
(betrouwbaarheidsinterval 0,058- 0,108, P<0,05) extremiteit/romp tumoren 
ontwikkelden hersenmetastasen. De 26 hoofd/hals patiënten (4 stadium I, 10 
stadium II, en 12 stadium III) hadden een mediane leeftijd van 46 jaar en 
ontwikkelden hersenmetastasen na een mediane periode van 24 maanden. De 
mediane Breslow dikte van hun tumoren bedroeg 3,3 mm. Behandeling bestond uit 
toediening van steroïden, chirurgie, bestraling, chemotherapie of een combinatie 
hiervan. De mediane overleving gerekend vanaf het ontstaan van 
hersenmetastasen was 2,4 maanden, met een éénjaars overleving van 15%. Als 
risicofactoren voor het ontstaan van hersenmetastasen vanuit hoofd/hals 
melanomen kwamen jongere leeftijd, mannelijk geslacht, Breslow dikte meer dan 4 
mm en mitose ratio naar voren. Hoofd/hals CM geven in 8% aanleiding tot 
hersenmetastasering tegen 5,2% van extremiteit/romp melanomen; het ontstaan 
van hersenmetastasen is geassocieerd met bovenstaande prognostische factoren. 
De prognose van de patiënten met hersenmetastasendeze is met de huidige 
beschikbare behandelingsmogelijkheden nog steeds slecht. Metastasectomie en 
adjuvante radiotherapie voor solitaire hersenmetastasen kunnen in geselecteerde 
gevallen de overleving verlengen. 
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  Conclusies 
 
•  Geïsoleerde hyperthermische ledemaat perfusie met melfalan heeft zich 
ontwikkeld tot een volwaardige palliatieve behandelingsmodaliteit voor 
intransit metastasen en/of recidieven bij patiënten die niet voor een lokale 
chirurgische ingreep in aanmerking komen. 
•  Geïsoleerde hyperthermische ledemaat perfusie met carboplatine in de 
behandeling van lokaal uitgebreide melanomen gaat gepaard met ernstige 
neurotoxiciteit van het behandelde ledemaat. 
•  Continue uitwendige monitoring met 131I-albumine als belangrijkste 
isotoop is een betrouwbare methode om lekkage van het perfusaat naar de 
systemische circulatie te detecteren. 
•  Zwangerschap heeft geen ongunstige invloed op de lange-termijn 
uitkomst van patiënten met een primair stadium I of II melanoom. 
•  De lange-termijn uitkomst voor kinderen/juvenielen met een melanoom is 
vergelijkbaar met die van volwassen patiënten. Echter, behalve het 
ziektestadium ten tijde van de presentatie van de ziekte, zijn de huidig 
bekende prognostische factoren niet van toepassing op 
kinderen/juvenielen met een melanoom. 
•  Er is een verhoogde incidentie van hersenmetastasen afkomstig van cutane 
hoofd/hals melanomen ten opzichte van cutane melanomen van romp en 
extremiteiten. ________________________________________                  C h a p t e r  I X 
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  Vooruitblik 
 
Hoewel conventionele ILP een effectieve modaliteit is in de behandeling van 
recidief melanomen van arm of been, blijft het een complexe en invasieve 
procedure. Er geldt een strikte patiënten-selectie zodat veel patiënten niet 
behandeld kunnen worden. Zo worden vaak patiënten met afstandsmetasasen 
naast een recidief aan het ledemaat, en patiënten met ernstige co-morbiditeit veelal 
uitgesloten van ILP behandeling. In 1994 werd door Thompson van de Sydney 
melanoma unit een gesimplificeerde methodiek van ILP, namelijk geïsoleerde 
ledemaat infusie (ILI), geïntroduceerd. Deze nieuwe techniek is feitelijk een ILP 
met lage stroomsnelheid die onder hypoxische condities wordt uitgevoerd met 
klein-caliber arteriële en veneuze katheters, die percutaan worden opgevoerd via 
de contralaterale lies. Vanwege de lage drukken die hiermee worden gegenereerd, 
is een pneumatische tourniquet afdoende om systemische lekkage van de 
gebruikte chemotherapeutische middelen te voorkomen. Het is bij deze techniek 
echter niet mogelijk om de temperatuur in arm of been boven de 38,5 C op te 
voeren. De ILI procedure heeft mogelijk een equivalente effectiviteit ten opzichte 
van ILP en zou toegepast kunne worden bij de oudere en medisch 
gecompromitteerde patiënt. Bijkomend voordeel is dat de ILI-procedure 
herhaaldelijk kan worden uitgevoerd en vormen afstandsmetastasen geen contra-
indicatie. 
 
De ziekte melanoom is anno 2004 nog steeds onvoorstelbaar en onvoorspelbaar De 
enige kans op genezing biedt  radicale chirurgische verwijdering(en) van 
melano(o)m(en) en van de eventuele metastasen. De komende jaren zal door de 
afdeling Chirurgische Oncologie van het GUMC en andere instituten de waarde 
van de schildwachtklierbiopsie bij het melanoom stadium I (MSLT I en II studie), 
d e  w h o l e - b o d y  C T  s c a n  e n  w h o l e - b o d y  P E T  s c a n  ( O M S P E C T  s t u d i e )  b i j  d e  
stadiering van het locoregionaal gemetastaseerde melanoom (stadium III) en de 
behandeling met een polyvalent melanoom vaccin bij het gemetastaseerde 
melanoom (stadium III en IV) onderzocht worden. Daarnaast zal onderzoek naar 
de waarde van follow-up bij het melanoom (MELFON studie) geinitieerd worden.  _____________________________________________________________ 
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1.  Geïsoleerde hyperthermische ledemaatperfusie met melfalan heeft zich 
ontwikkeld tot een volwaardige palliatieve behandeling van intransit 
metastasen en/of recidief melanomen die niet voor een lokale chirurgische 
ingreep in aanmerking komen. 
 
2.  Geïsoleerde hyperthermische ledemaatperfusie met carboplatine gaat 
gepaard met ernstige neurotoxiciteit van de behandelde extremiteit. 
 
3.  Het optreden van systemische toxiciteit bij perfusie van een extremiteit met 
TNFα heeft ertoe geleid dat chirurgen bij het uitvoeren van de perfusie meer 
bedacht zijn op het voorkómen van lekkage. 
 
4.  Continue uitwendige controle met 131I-albumine als belangrijkste isotoop is 
een betrouwbare methode om lekkage van het perfusaat naar de systemische 
circulatie op te sporen. 
 
5.  Het bestaan van een zwangerschap bij de presentatie van een primair 
stadium I of II melanoom van de huid heeft geen ongunstige invloed op de 
overleving van de moeder.  
 
6.  In vergelijking met volwassenen is er bij patiënten jonger dan 19 jaar met een 
melanoom van de huid vaker sprake van een stadium III bij presentatie. 
 
7.  De keuze van de Nederlandse Antillen en Aruba voor UPG (Ultraperifeer 
Gebied) of LGO (Landen en Gebieden Overzee) moet niet de uitkomst zijn 
van een boekhoudkundige exercitie. Het is een politieke keuze, waarbij het 
van belang is zich af te vragen wat voor land Aruba en de Antillen op de 
lange termijn willen zijn in relatie tot de rest van de wereld. 
 
  
8.  Veel van de belangrijke culturele overeenkomsten en verschillen tussen 
mensen in de hedendaagse wereld zijn eerder verbonden met het beroep dan 
met de nationaliteit. 
 
9.  Democracy must, in essence, mean the art and science of mobilizing the 
entire physical, economic and spiritual resources of all the various sections of 
the people in the service of the common good of all.  
(Mahatma Gandhi, Mohandas Karamchad Gandhi, 1869-1948) 
 
10.  Evenals de primitieve tovenaar wordt de deskundige aangemoedigd zich 
bezig te houden met zijn geheimzinnige berekeningen, en blijft 
geloofwaardig ook als de gebeurtenissen hem in het ongelijk stellen.  
(Gareth Morgan, Images of Organization, Sage Publications 1986) 
 
11.  Until we are able to control human overpopulation, any species that 
competes with ‘Homo sapiens’ for space and food is doomed.  
(Karla Kellenberger, Time Magazine,Volume 164, nummer 11, September 13, 2004) 
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